MOGAD

Neurological Disorder MONDO:1040024 Pathograph 9 Autoimmune Disorder Demyelinating Disease

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune inflammatory demyelinating disorder of the central nervous system defined by serum IgG autoantibodies against conformational epitopes of MOG. MOGAD typically presents as acute disseminated encephalomyelitis (ADEM, more common in children), optic neuritis, or transverse myelitis, and less commonly as cerebral cortical encephalitis, brainstem, or cerebellar syndromes. It is clinically and pathologically distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD). Disease course can be monophasic or relapsing, and diagnosis relies on cell-based assays detecting MOG-IgG with full-length human MOG in its native conformation.

Ask OpenScientist

Ask a research question about MOGAD. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
4
Histopath.
13
Phenotypes
9
Pathograph
7
Treatments
2
Subtypes
4
Trials
13
References
2
Deep Research
◆

Subtypes

2
Monophasic MOGAD
A single clinical episode of CNS demyelination with no further attacks during follow-up. The monophasic proportion varies by cohort definition, follow-up duration, and age distribution, with recent population-based data reporting a majority monophasic course over medium-term follow-up.
Show evidence (2 references)
PMID:40088708 SUPPORT Human Clinical
"The disease course is either monophasic or relapsing, with relapsing course affecting approximately two-thirds of individuals."
Andersen and Brilot 2025 review confirms that MOGAD can be either monophasic or relapsing, with relapsing disease prominent in many referred cohorts.
PMID:41657079 SUPPORT Human Clinical
"64.5% had a monophasic disease course"
A population-based South Wales cohort applying the 2023 diagnostic criteria found that most identified MOGAD cases remained monophasic over median 38-month follow-up.
Relapsing MOGAD
Recurrent demyelinating attacks; relapse risk is higher in referral and adult cohorts and increases with follow-up. Relapsing MOGAD typically presents with recurrent optic neuritis with or without transverse myelitis, often with persistent MOG-IgG seropositivity.
Show evidence (2 references)
PMID:40088708 SUPPORT Human Clinical
"The disease course is either monophasic or relapsing, with relapsing course affecting approximately two-thirds of individuals."
A relapsing course occurs in approximately two-thirds of MOGAD patients according to the Andersen and Brilot 2025 review.
PMID:29695592 SUPPORT Human Clinical
"The probability of reaching a first relapse after 2 and 5 years was 44.8% and 61.8%, respectively."
MOGADOR cohort of 197 adult MOG-Ab-positive patients quantifies relapse probability over 2 and 5 years.
⚙

Pathophysiology

5
Anti-MOG Autoimmunity
The hallmark of MOGAD is the production of IgG autoantibodies (predominantly IgG1) targeting conformational epitopes on myelin oligodendrocyte glycoprotein, a quantitatively minor myelin protein expressed exclusively on the outermost surface of CNS myelin and on oligodendrocyte membranes. MOG is therefore directly accessible to circulating antibodies that breach the blood-brain barrier. Detection of pathogenic MOG-IgG requires cell-based assays presenting full-length human MOG in its native conformation; older immunoblot/ELISA assays detect non-pathogenic linear-epitope antibodies and are not specific for MOGAD.
oligodendrocyte link
myelin sheath link
Downstream
Complement-Dependent Cytotoxicity MOG-IgG1 binding to oligodendrocyte surface MOG triggers classical complement activation.
Antibody-Dependent Cellular Cytotoxicity MOG-IgG bound to oligodendrocytes engages Fc-gamma receptors on myeloid and NK effector cells.
Cognate T-Cell Mediated Inflammation Pathogenic effector mechanisms of MOG-IgG depend on cooperation with cognate MOG-specific T cells.
Show evidence (2 references)
PMID:36706773 SUPPORT Human Clinical
"Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder."
The Banwell et al. 2023 international MOGAD Panel diagnostic criteria establish MOG-IgG as the defining serological feature distinguishing MOGAD from MS and AQP4-IgG NMOSD.
PMID:36706773 SUPPORT Human Clinical
"MOG-IgG cell-based assays are important for diagnostic accuracy."
Cell-based assays presenting native MOG are required to detect pathogenic conformational MOG-IgG.
Complement-Dependent Cytotoxicity
MOG-IgG (predominantly IgG1) bound to MOG on the surface of oligodendrocytes activates the classical complement pathway, leading to membrane attack complex formation and oligodendrocyte injury with secondary demyelination. Unlike AQP4-IgG NMOSD where astrocytes are the primary target, in MOGAD oligodendrocytes/myelin are directly targeted.
oligodendrocyte link
complement activation link ↑ INCREASED
Downstream
Oligodendrocyte Cytoskeleton Disruption and Demyelination Membrane attack complex formation causes oligodendrocyte injury that converges on the demyelination phenotype.
Show evidence (2 references)
PMID:40088708 SUPPORT Human Clinical
"MOG-IgG-mediated demyelination occurs via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), enhanced cognate T-cell CNS infiltration and activation, and oligodendrocyte cytoskeleton disruption"
The Andersen and Brilot 2025 review enumerates complement-dependent cytotoxicity as a primary effector mechanism of MOG-IgG-mediated demyelination.
PMID:32048003 SUPPORT Human Clinical
"Complement deposition is present in all active white matter lesions"
Autopsy/biopsy pathology directly documents complement deposition in active MOGAD white matter lesions, supporting complement-mediated tissue injury.
Antibody-Dependent Cellular Cytotoxicity
Beyond classical complement activation, MOG-IgG bound to oligodendrocytes engages Fc-gamma receptors on macrophages, NK cells, and microglia, triggering antibody-dependent cellular cytotoxicity (ADCC) and additional oligodendrocyte/myelin injury.
antibody-dependent cellular cytotoxicity link ↑ INCREASED
Downstream
Oligodendrocyte Cytoskeleton Disruption and Demyelination Fc-receptor-mediated effector-cell killing of antibody-coated oligodendrocytes converges on demyelination.
Show evidence (1 reference)
PMID:40088708 SUPPORT Human Clinical
"MOG-IgG-mediated demyelination occurs via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), enhanced cognate T-cell CNS infiltration and activation, and oligodendrocyte cytoskeleton disruption"
ADCC is described as a co-effector mechanism of MOG-IgG-mediated demyelination in the Andersen and Brilot 2025 review.
Cognate T-Cell Mediated Inflammation
MOG-specific T cells contribute to CNS infiltration and to the activation of antibody-mediated effector mechanisms. Pathogenicity of human MOG-IgG in experimental models depends on cognate MOG-specific T-cell help, indicating that humoral and cellular autoimmunity act in concert.
CD4-positive T cell link
Downstream
Oligodendrocyte Cytoskeleton Disruption and Demyelination Cognate T-cell CNS infiltration and inflammation enhance the antibody-driven demyelination programme.
Show evidence (2 references)
PMID:40088708 SUPPORT Human Clinical
"enhanced cognate T-cell CNS infiltration and activation"
The Andersen and Brilot 2025 review describes enhanced cognate T-cell CNS infiltration and activation as part of MOG-IgG-mediated demyelination.
PMID:32048003 SUPPORT Human Clinical
"A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates."
MOGAD autopsy/biopsy pathology documents CD4-positive T-cell dominated inflammatory infiltrates, justifying the more specific CD4-positive alpha-beta T cell descriptor for this inflammatory mechanism.
Oligodendrocyte Cytoskeleton Disruption and Demyelination
MOG-IgG binding can directly disrupt the oligodendrocyte cytoskeleton, impairing myelin sheath maintenance and causing secondary demyelination. Demyelination in MOGAD often shows perivenous confluent lesions with relative axonal preservation, contrasting with the AQP4-IgG NMOSD pattern of astrocyte loss-driven necrosis.
oligodendrocyte link
myelination link ↓ DECREASED
myelin sheath link
Show evidence (2 references)
PMID:40088708 SUPPORT Human Clinical
"oligodendrocyte cytoskeleton disruption"
The Andersen and Brilot 2025 review identifies oligodendrocyte cytoskeleton disruption as a direct effect of MOG-IgG binding.
PMID:32412053 SUPPORT Human Clinical
"Most demyelinating lesions in 10 of 11 cases showed a perivenous demyelinating pattern previously reported in ADEM (153/167 lesions) and a fusion pattern (11/167 lesions)"
Brain biopsy pathology confirms perivenous inflammatory demyelination as a characteristic lesion pattern in MOG antibody-associated disease.
✶

Histopathology

4
Perivenous and confluent CNS demyelination
MOGAD biopsy and autopsy specimens show perivenous and confluent demyelinating lesions in white matter, with intracortical demyelination over-represented compared with typical multiple sclerosis.
Show evidence (2 references)
PMID:32048003 SUPPORT Human Clinical
"MOGAD pathology is dominated by coexistence of both perivenous and confluent white matter demyelination"
This autopsy/biopsy cohort defines the mixed perivenous and confluent demyelinating lesion architecture characteristic of MOGAD.
PMID:32412053 SUPPORT Human Clinical
"Most demyelinating lesions in 10 of 11 cases showed a perivenous demyelinating pattern previously reported in ADEM (153/167 lesions) and a fusion pattern (11/167 lesions)"
Independent brain-biopsy pathology confirms that perivenous demyelination is common across MOG antibody-associated disease lesions.
CD4-positive T-cell and granulocytic inflammatory infiltrate
Active MOGAD lesions show CD4-positive T-cell dominated inflammation with granulocytic infiltration, supporting a mixed cellular and humoral immunopathology rather than a classic MS plaque pattern.
Show evidence (2 references)
PMID:32048003 SUPPORT Human Clinical
"A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates."
This directly supports CD4-positive T-cell dominant inflammatory infiltrates as a characteristic MOGAD lesion feature.
PMID:32412053 SUPPORT Human Clinical
"with CD4-dominance (CD4+ versus CD8+; 1281 ± 1196 cells/mm2 versus 851 ± 762 cells/mm2, P < 0.01)"
Quantitative biopsy immunophenotyping supports CD4-positive T-cell predominance in MOG antibody-associated demyelinating lesions.
Complement deposition in active white matter lesions
Active MOGAD white matter lesions show complement deposition, consistent with humoral effector mechanisms contributing to myelin injury.
Show evidence (1 reference)
PMID:32048003 SUPPORT Human Clinical
"Complement deposition is present in all active white matter lesions"
Complement deposition in active lesions is a microscopic correlate of the complement-dependent effector mechanism modelled in pathophysiology.
Preserved AQP4 without dystrophic astrocytes
MOGAD lesions preserve aquaporin-4 expression and lack dystrophic astrocytes, distinguishing MOGAD pathology from AQP4-IgG-positive NMOSD astrocytopathy.
Show evidence (1 reference)
PMID:32048003 SUPPORT Human Clinical
"AQP4 is preserved, with absence of dystrophic astrocytes"
Astrocyte and AQP4 preservation supports MOGAD as pathologically distinct from AQP4-IgG NMOSD, where astrocytopathy is central.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for MOGAD Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Eye 3
Optic Neuritis Optic neuritis (HP:0100653)
Show evidence (2 references)
PMID:36706773 SUPPORT Human Clinical
"MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis"
Optic neuritis is one of the three core clinical phenotypes of MOGAD per the 2023 international diagnostic criteria.
PMID:29695592 SUPPORT Human Clinical
"Clinical phenotype at onset included optic neuritis or myelitis in 90.86%"
In the MOGADOR adult cohort, optic neuritis or myelitis was the onset phenotype in over 90% of MOG-IgG-positive patients.
Visual Loss Visual loss (HP:0000572)
Show evidence (1 reference)
PMID:40088708 PARTIAL Human Clinical
"Neurological disability accumulates with relapse and may manifest as visual, motor, sensory, and cognitive deficits."
Visual deficits are recognised as one of the major outcome domains in relapsing MOGAD; PARTIAL because the snippet refers to disability accrual rather than the acute visual loss phenotype itself.
Optic Disc Swelling Papilledema (HP:0001085)
HPO does not have a separate term for "optic disc edema due to optic neuritis"; the closest standard label is HP:0001085 Papilledema.
Show evidence (1 reference)
PMID:34418402 PARTIAL Human Clinical
"Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination."
Optic disc edema is a well-described imaging/fundoscopic feature of MOGAD optic neuritis. The cited Lancet Neurology overview supports MOGAD as a CNS demyelinating disease; the disc-edema specificity is established in the broader Marignier review body but not captured in the abstract, hence PARTIAL.
Immune 1
Transverse Myelitis Myelitis (HP:0012486)
Show evidence (1 reference)
PMID:36706773 SUPPORT Human Clinical
"MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis"
Transverse myelitis is one of the three core clinical phenotypes of MOGAD per the 2023 international diagnostic criteria.
Nervous System 7
Acute Disseminated Encephalomyelitis CNS demyelination (HP:0007305)
HPO lacks a dedicated term for ADEM; the closest concept is HP:0007305 CNS demyelination, with `preferred_term` capturing the specific syndrome name.
Show evidence (2 references)
PMID:36706773 SUPPORT Human Clinical
"MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis"
ADEM is one of the three core clinical phenotypes of MOGAD per the 2023 international diagnostic criteria.
PMID:30559466 SUPPORT Human Clinical
"Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM)."
The Reindl and Waters 2019 review traces the original recognition of MOG-Abs in pediatric ADEM patients.
Encephalopathy Encephalopathy (HP:0001298)
Show evidence (1 reference)
PMID:29695592 SUPPORT Human Clinical
"isolated brainstem or encephalopathy syndromes in 6.6%"
Encephalopathy is recognised as an isolated onset phenotype in 6.6% of adult MOGAD patients in the MOGADOR cohort.
Cerebral Cortical Encephalitis CNS demyelination (HP:0007305)
HPO does not provide a non-infectious "cortical encephalitis" term and HP:0002383 Infectious encephalitis is semantically incorrect (autoimmune, not infectious). HP:0007305 CNS demyelination is used as the closest valid umbrella concept; `preferred_term` retains the specific clinical syndrome name. NTR for an HPO autoimmune cortical encephalitis term may be warranted.
Show evidence (1 reference)
PMID:36706773 SUPPORT Human Clinical
"less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations"
Cerebral cortical encephalitis is recognised as a less common but bona fide MOGAD phenotype in the 2023 international criteria.
Seizure Seizure (HP:0001250)
Show evidence (1 reference)
PMID:30559466 SUPPORT Human Clinical
"Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes"
Seizures are recognised among the spectrum of MOG-Ab-associated neurological presentations in the Reindl and Waters 2019 review.
Headache Headache (HP:0002315)
Show evidence (1 reference)
PMID:30559466 PARTIAL Human Clinical
"Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes"
Headache is a typical accompanying symptom of MOG-associated encephalitis presentations enumerated in this review; the snippet supports the encephalitis context but does not name headache explicitly, so PARTIAL.
Brainstem Syndrome CNS demyelination (HP:0007305)
HPO does not have a single term for "brainstem demyelinating syndrome"; HP:0007305 CNS demyelination is used as the umbrella concept and the `preferred_term` provides the clinical specificity.
Show evidence (1 reference)
PMID:36706773 SUPPORT Human Clinical
"less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations"
Brainstem presentations are explicitly listed as a recognised MOGAD phenotype in the 2023 international diagnostic criteria.
Ataxia Ataxia (HP:0001251)
Show evidence (1 reference)
PMID:36706773 PARTIAL Human Clinical
"less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations"
Brainstem and cerebellar presentations are recognised MOGAD phenotypes; ataxia is the dominant clinical sign of cerebellar involvement. Indirect support, hence PARTIAL.
Other 2
Spinal Cord Lesion Spinal cord lesion (HP:0100561)
Show evidence (1 reference)
PMID:34418402 SUPPORT Human Clinical
"Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination."
The Marignier et al. 2021 Lancet Neurology review establishes MOGAD as an inflammatory CNS demyelinating disease with characteristic spinal cord involvement.
Paraparesis Paraparesis (HP:0002385)
Show evidence (1 reference)
PMID:40088708 PARTIAL Human Clinical
"Neurological disability accumulates with relapse and may manifest as visual, motor, sensory, and cognitive deficits."
Motor deficits in MOGAD are predominantly driven by transverse myelitis presenting as paraparesis. The snippet supports motor deficit accrual; PARTIAL because it does not name paraparesis specifically.
💊

Treatments

7
Acute Attack Treatment - High-Dose Corticosteroids
Action: systemic corticosteroid therapy Ontology label: Systemic Corticosteroid Therapy NCIT:C122080
High-dose intravenous methylprednisolone (typically 1 g daily for 3-5 days) is first-line therapy for acute MOGAD attacks. Many neurologists follow with a slow oral prednisone taper to reduce early relapse risk, given that abrupt steroid withdrawal in the months after an attack is associated with new attacks in MOGAD.
Show evidence (2 references)
PMID:40708693 SUPPORT Human Clinical
"Acute MOGAD attacks are generally responsive to high-dose corticosteroids"
The Wolf et al. 2023 review confirms high-dose corticosteroids as effective first-line acute attack therapy in MOGAD.
PMID:40708693 SUPPORT Human Clinical
"A slow corticosteroid taper may lower the risk of relapse."
Wolf et al. 2023 supports the practice of a slow steroid taper to mitigate early post-attack relapses in MOGAD.
Acute Attack Treatment - Plasma Exchange
Action: plasmapheresis Ontology label: Plasmapheresis NCIT:C15304
Therapeutic plasma exchange (plasmapheresis) is used for severe MOGAD attacks not responding to corticosteroids. Removes circulating MOG-IgG and other inflammatory mediators.
Mechanism Target:
INHIBITS Anti-MOG Autoimmunity — Plasma exchange physically removes circulating MOG-IgG, blunting the pathogenic autoantibody load.
Show evidence (1 reference)
PMID:40708693 SUPPORT Human Clinical
"early use of plasma exchange or intravenous immunoglobulin may be beneficial for severe attacks or cases lacking corticosteroid response"
Wolf et al. 2023 review supports plasma exchange as escalation therapy for severe or steroid-refractory MOGAD attacks.
Maintenance - Intravenous Immunoglobulin
Action: intravenous immunoglobulin therapy Ontology label: immunoglobulin infusion therapy MAXO:0001480
Maintenance intravenous immunoglobulin (IVIG) is used in relapsing MOGAD, particularly in pediatric patients, with retrospective evidence suggesting favourable relapse-prevention compared to other immunosuppressants. Given typically every 3-4 weeks at maintenance dosing.
Mechanism Target:
INHIBITS Anti-MOG Autoimmunity — IVIG modulates pathogenic autoantibody activity through Fc-receptor saturation, complement scavenging, idiotype neutralisation, and immune-cell modulation, attenuating MOG-IgG-driven CNS injury.
Show evidence (2 references)
PMID:34634625 SUPPORT Human Clinical
"mIVIG 25.3% [95%CI 14.0% to 41.3%; ARR 0.081 (0.058)]."
Meta-analysis of maintenance immunotherapies found the lowest pooled relapse probability and annualized relapse rate with maintenance IVIG.
PMID:35377395 SUPPORT Human Clinical
"The median (range) annualized relapse rate before IVIG treatment was 1.4 (0-6.1), compared with a median (range) annualized relapse rate while receiving IVIG of 0 (0-3)"
Multicenter adult cohort data directly supports maintenance IVIG as a relapse-prevention therapy in MOGAD.
Maintenance - Rituximab
Action: Pharmacotherapy NCIT:C15986
Agent: rituximab ↗
Anti-CD20 monoclonal antibody used as maintenance therapy in relapsing MOGAD. Effectiveness is more modest than in AQP4-IgG NMOSD or MS, with relapses occurring even during apparent B-cell depletion in a substantial minority of patients.
Mechanism Target:
INHIBITS Anti-MOG Autoimmunity — Rituximab depletes CD20+ B cells, reducing the population of cells that can differentiate into MOG-IgG-producing antibody-secreting cells. Long-lived CD20-negative plasma cells likely explain incomplete efficacy.
Show evidence (2 references)
PMID:32629363 SUPPORT Human Clinical
"RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion."
The Whittam et al. 2020 international study of 121 MOGAD patients demonstrated rituximab efficacy with limitations.
PMID:32629363 PARTIAL Human Clinical
"RTX led to a 37% decline in relapse rate, and after 2 years, 33% of patients are predicted to remain relapse-free."
The treatment effect is partial - rituximab reduces but does not abolish MOGAD relapses, with only one-third remaining relapse-free at 2 years.
Maintenance - Tocilizumab
Action: Pharmacotherapy NCIT:C15986
Agent: tocilizumab ↗
Anti-IL-6 receptor monoclonal antibody used in rituximab-refractory or severely relapsing MOGAD. IL-6 is implicated in plasmablast survival and autoantibody production.
Mechanism Target:
INHIBITS Anti-MOG Autoimmunity — IL-6 receptor blockade reduces plasmablast survival and Th17/T-cell help that sustain MOG-IgG production.
INHIBITS Cognate T-Cell Mediated Inflammation — IL-6 signalling drives Th17 differentiation and effector T-cell activation in CNS demyelinating disease; tocilizumab attenuates this arm of MOGAD pathophysiology.
Show evidence (1 reference)
PMID:32629363 SUPPORT Human Clinical
"Tocilizumab (interleukin-6 blockade) has been used effectively in some patients with RTX-refractory MOGAD"
Tocilizumab is reported as an effective option in rituximab-refractory MOGAD in the Whittam et al. 2020 cohort discussion.
Maintenance - Mycophenolate Mofetil
Action: Pharmacotherapy NCIT:C15986
Agent: mycophenolate mofetil ↗
Oral immunosuppressant used as a steroid-sparing maintenance therapy in relapsing MOGAD, frequently in combination with low-dose oral prednisone.
Show evidence (1 reference)
PMID:40708693 PARTIAL Human Clinical
"Preventative treatment has been typically limited to patients with a definitive relapsing disease. While there is no consensus on the choice or duration of treatment, multiple therapies have been retrospectively evaluated."
MMF is one of the off-label maintenance therapies retrospectively evaluated in relapsing MOGAD; the Wolf et al. 2023 review summarises this evidence base. PARTIAL because the abstract does not call out MMF specifically.
Maintenance - Azathioprine
Action: Pharmacotherapy NCIT:C15986
Agent: azathioprine ↗
Oral purine-analog immunosuppressant used as a steroid-sparing maintenance therapy in relapsing MOGAD. Often combined with low-dose oral prednisone until therapeutic effect is achieved.
Show evidence (1 reference)
PMID:40708693 PARTIAL Human Clinical
"Preventative treatment has been typically limited to patients with a definitive relapsing disease. While there is no consensus on the choice or duration of treatment, multiple therapies have been retrospectively evaluated."
Azathioprine is among the off-label maintenance therapies retrospectively evaluated in relapsing MOGAD per the Wolf et al. 2023 review. PARTIAL because the abstract does not call out azathioprine by name.
🔬

Clinical Trials

4
NCT05271409 PHASE_III RECRUITING
Phase 3 randomized, double-blind trial evaluating satralizumab versus placebo, as monotherapy or added to baseline therapy, for prevention of adjudicated MOGAD relapse.
Show evidence (1 reference)
clinicaltrials:NCT05271409 SUPPORT Human Clinical
"The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period."
ClinicalTrials.gov documents an ongoing randomized phase 3 relapse prevention trial of satralizumab in MOGAD.
NCT05063162 PHASE_III ACTIVE_NOT_RECRUITING
Phase 3 randomized, double-blind placebo-controlled pivotal trial with open-label extension evaluating rozanolixizumab in adults with MOGAD.
Show evidence (1 reference)
clinicaltrials:NCT05063162 SUPPORT Human Clinical
"The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD)."
ClinicalTrials.gov documents a phase 3 FcRn-inhibition trial in adult MOGAD participants.
NCT05349006 PHASE_III RECRUITING
Randomized placebo-controlled phase 3 trial testing azathioprine after a first MOGAD attack to prevent relapse and disability accrual.
Show evidence (1 reference)
clinicaltrials:NCT05349006 SUPPORT Human Clinical
"The investigators propose herein the first randomized controlled trial in MOGAD, to evaluate the efficacy of azathioprine to prevent relapses, after a first attack, in a placebo double-blinded design."
ClinicalTrials.gov documents a randomized phase 3 azathioprine relapse prevention trial in MOGAD.
NCT06452537 PHASE_II ACTIVE_NOT_RECRUITING
Randomized controlled multicenter phase 2/3 trial evaluating tocilizumab safety and efficacy in MOGAD.
Show evidence (1 reference)
clinicaltrials:NCT06452537 SUPPORT Human Clinical
"The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD."
ClinicalTrials.gov documents an active randomized trial of IL-6 receptor blockade with tocilizumab in MOGAD.
{ }

Source YAML

click to show 
name: MOGAD
creation_date: "2026-05-03T00:00:00Z"
updated_date: "2026-05-16T03:56:08Z"
category: Neurological Disorder
parents:
- Autoimmune Disorder
- Demyelinating Disease
disease_term:
  preferred_term: myelin oligodendrocyte glycoprotein antibody-associated disease
  term:
    id: MONDO:1040024
    label: myelin oligodendrocyte glycoprotein antibody-associated disease
description: >
  Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an
  autoimmune inflammatory demyelinating disorder of the central nervous system
  defined by serum IgG autoantibodies against conformational epitopes of MOG.
  MOGAD typically presents as acute disseminated encephalomyelitis (ADEM, more
  common in children), optic neuritis, or transverse myelitis, and less commonly
  as cerebral cortical encephalitis, brainstem, or cerebellar syndromes. It is
  clinically and pathologically distinct from multiple sclerosis (MS) and
  aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
  (AQP4-IgG NMOSD). Disease course can be monophasic or relapsing, and
  diagnosis relies on cell-based assays detecting MOG-IgG with full-length human
  MOG in its native conformation.
has_subtypes:
- name: Monophasic MOGAD
  description: >
    A single clinical episode of CNS demyelination with no further attacks
    during follow-up. The monophasic proportion varies by cohort definition,
    follow-up duration, and age distribution, with recent population-based data
    reporting a majority monophasic course over medium-term follow-up.
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease course is either monophasic or relapsing, with relapsing course affecting approximately two-thirds of individuals."
    explanation: >
      Andersen and Brilot 2025 review confirms that MOGAD can be either
      monophasic or relapsing, with relapsing disease prominent in many
      referred cohorts.
  - reference: PMID:41657079
    reference_title: "MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "64.5% had a monophasic disease course"
    explanation: >
      A population-based South Wales cohort applying the 2023 diagnostic
      criteria found that most identified MOGAD cases remained monophasic over
      median 38-month follow-up.
- name: Relapsing MOGAD
  description: >
    Recurrent demyelinating attacks; relapse risk is higher in referral and
    adult cohorts and increases with follow-up. Relapsing MOGAD typically
    presents with recurrent optic neuritis with or without transverse myelitis,
    often with persistent MOG-IgG seropositivity.
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease course is either monophasic or relapsing, with relapsing course affecting approximately two-thirds of individuals."
    explanation: >
      A relapsing course occurs in approximately two-thirds of MOGAD patients
      according to the Andersen and Brilot 2025 review.
  - reference: PMID:29695592
    reference_title: "Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The probability of reaching a first relapse after 2 and 5 years was 44.8% and 61.8%, respectively."
    explanation: >
      MOGADOR cohort of 197 adult MOG-Ab-positive patients quantifies relapse
      probability over 2 and 5 years.
prevalence:
- population: Danish adult population, 2023 criteria
  percentage: "0.00151"
  notes: >
    Nationwide population-based adult prevalence estimate; equivalent to 1.51
    per 100,000 adults.
  evidence:
  - reference: PMID:41865559
    reference_title: "Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the prevalence was 1.51 per 100,000 persons"
    explanation: >
      Danish registry/laboratory case ascertainment provides a nationwide adult
      MOGAD prevalence estimate using the 2023 International MOGAD Panel
      criteria.
- population: South Wales population, 2023 criteria
  percentage: "0.00385"
  notes: >
    Regional population-based prevalence estimate on 30 June 2024; equivalent
    to 3.85 per 100,000 population.
  evidence:
  - reference: PMID:41657079
    reference_title: "MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "76/1,974,110 population (3.85/100,000 population; 95% CI 3.03-4.82)."
    explanation: >
      South Wales regional case ascertainment provides an updated MOGAD
      prevalence estimate after applying the 2023 diagnostic criteria.
epidemiology:
- name: Adult incidence in Denmark
  description: >
    Nationwide adult MOGAD incidence estimate using laboratory, registry, and
    neurology department ascertainment.
  minimum_value: 0.205
  unit: cases per 100000 person-years
  evidence:
  - reference: PMID:41865559
    reference_title: "Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOGAD in the Danish adult population was 0.205 per 100,000 person-years"
    explanation: >
      This population-based Danish study directly reports adult MOGAD
      incidence according to the 2023 criteria.
- name: Annual incidence in South Wales
  description: >
    Regional MOGAD annual incidence estimate for South Wales using cases from
    2015 through 2023.
  minimum_value: 3.39
  unit: cases per million population per year
  evidence:
  - reference: PMID:41657079
    reference_title: "MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean annual incidence was 3.39 (95% CI 2.58-4.39) per million population."
    explanation: >
      The South Wales population-based cohort provides an annual incidence
      estimate for MOGAD after adoption of the 2023 diagnostic criteria.
pathophysiology:
- name: Anti-MOG Autoimmunity
  description: >
    The hallmark of MOGAD is the production of IgG autoantibodies (predominantly
    IgG1) targeting conformational epitopes on myelin oligodendrocyte
    glycoprotein, a quantitatively minor myelin protein expressed exclusively on
    the outermost surface of CNS myelin and on oligodendrocyte membranes. MOG
    is therefore directly accessible to circulating antibodies that breach the
    blood-brain barrier. Detection of pathogenic MOG-IgG requires cell-based
    assays presenting full-length human MOG in its native conformation; older
    immunoblot/ELISA assays detect non-pathogenic linear-epitope antibodies and
    are not specific for MOGAD.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  cellular_components:
  - preferred_term: myelin sheath
    term:
      id: GO:0043209
      label: myelin sheath
  downstream:
  - target: Complement-Dependent Cytotoxicity
    description: >
      MOG-IgG1 binding to oligodendrocyte surface MOG triggers classical
      complement activation.
  - target: Antibody-Dependent Cellular Cytotoxicity
    description: >
      MOG-IgG bound to oligodendrocytes engages Fc-gamma receptors on
      myeloid and NK effector cells.
  - target: Cognate T-Cell Mediated Inflammation
    description: >
      Pathogenic effector mechanisms of MOG-IgG depend on cooperation
      with cognate MOG-specific T cells.
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder."
    explanation: >
      The Banwell et al. 2023 international MOGAD Panel diagnostic criteria
      establish MOG-IgG as the defining serological feature distinguishing
      MOGAD from MS and AQP4-IgG NMOSD.
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOG-IgG cell-based assays are important for diagnostic accuracy."
    explanation: >
      Cell-based assays presenting native MOG are required to detect
      pathogenic conformational MOG-IgG.
- name: Complement-Dependent Cytotoxicity
  description: >
    MOG-IgG (predominantly IgG1) bound to MOG on the surface of oligodendrocytes
    activates the classical complement pathway, leading to membrane attack
    complex formation and oligodendrocyte injury with secondary demyelination.
    Unlike AQP4-IgG NMOSD where astrocytes are the primary target, in MOGAD
    oligodendrocytes/myelin are directly targeted.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: INCREASED
  downstream:
  - target: Oligodendrocyte Cytoskeleton Disruption and Demyelination
    description: >
      Membrane attack complex formation causes oligodendrocyte injury that
      converges on the demyelination phenotype.
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOG-IgG-mediated demyelination occurs via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), enhanced cognate T-cell CNS infiltration and activation, and oligodendrocyte cytoskeleton disruption"
    explanation: >
      The Andersen and Brilot 2025 review enumerates complement-dependent
      cytotoxicity as a primary effector mechanism of MOG-IgG-mediated
      demyelination.
  - reference: PMID:32048003
    reference_title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complement deposition is present in all active white matter lesions"
    explanation: >
      Autopsy/biopsy pathology directly documents complement deposition in
      active MOGAD white matter lesions, supporting complement-mediated tissue
      injury.
- name: Antibody-Dependent Cellular Cytotoxicity
  description: >
    Beyond classical complement activation, MOG-IgG bound to oligodendrocytes
    engages Fc-gamma receptors on macrophages, NK cells, and microglia,
    triggering antibody-dependent cellular cytotoxicity (ADCC) and additional
    oligodendrocyte/myelin injury.
  biological_processes:
  - preferred_term: antibody-dependent cellular cytotoxicity
    term:
      id: GO:0001788
      label: antibody-dependent cellular cytotoxicity
    modifier: INCREASED
  downstream:
  - target: Oligodendrocyte Cytoskeleton Disruption and Demyelination
    description: >
      Fc-receptor-mediated effector-cell killing of antibody-coated
      oligodendrocytes converges on demyelination.
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOG-IgG-mediated demyelination occurs via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), enhanced cognate T-cell CNS infiltration and activation, and oligodendrocyte cytoskeleton disruption"
    explanation: >
      ADCC is described as a co-effector mechanism of MOG-IgG-mediated
      demyelination in the Andersen and Brilot 2025 review.
- name: Cognate T-Cell Mediated Inflammation
  description: >
    MOG-specific T cells contribute to CNS infiltration and to the activation of
    antibody-mediated effector mechanisms. Pathogenicity of human MOG-IgG in
    experimental models depends on cognate MOG-specific T-cell help, indicating
    that humoral and cellular autoimmunity act in concert.
  cell_types:
  - preferred_term: CD4-positive T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  downstream:
  - target: Oligodendrocyte Cytoskeleton Disruption and Demyelination
    description: >
      Cognate T-cell CNS infiltration and inflammation enhance the
      antibody-driven demyelination programme.
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "enhanced cognate T-cell CNS infiltration and activation"
    explanation: >
      The Andersen and Brilot 2025 review describes enhanced cognate T-cell
      CNS infiltration and activation as part of MOG-IgG-mediated
      demyelination.
  - reference: PMID:32048003
    reference_title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates."
    explanation: >
      MOGAD autopsy/biopsy pathology documents CD4-positive T-cell dominated
      inflammatory infiltrates, justifying the more specific CD4-positive
      alpha-beta T cell descriptor for this inflammatory mechanism.
- name: Oligodendrocyte Cytoskeleton Disruption and Demyelination
  description: >
    MOG-IgG binding can directly disrupt the oligodendrocyte cytoskeleton,
    impairing myelin sheath maintenance and causing secondary demyelination.
    Demyelination in MOGAD often shows perivenous confluent lesions with
    relative axonal preservation, contrasting with the AQP4-IgG NMOSD pattern
    of astrocyte loss-driven necrosis.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  cellular_components:
  - preferred_term: myelin sheath
    term:
      id: GO:0043209
      label: myelin sheath
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oligodendrocyte cytoskeleton disruption"
    explanation: >
      The Andersen and Brilot 2025 review identifies oligodendrocyte
      cytoskeleton disruption as a direct effect of MOG-IgG binding.
  - reference: PMID:32412053
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most demyelinating lesions in 10 of 11 cases showed a perivenous
      demyelinating pattern previously reported in ADEM (153/167 lesions) and a
      fusion pattern (11/167 lesions)
    explanation: >
      Brain biopsy pathology confirms perivenous inflammatory demyelination as
      a characteristic lesion pattern in MOG antibody-associated disease.
histopathology:
- name: Perivenous and confluent CNS demyelination
  description: >-
    MOGAD biopsy and autopsy specimens show perivenous and confluent
    demyelinating lesions in white matter, with intracortical demyelination
    over-represented compared with typical multiple sclerosis.
  diagnostic: true
  context: CNS biopsy/autopsy pathology in MOG-IgG-positive inflammatory demyelination
  evidence:
  - reference: PMID:32048003
    reference_title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOGAD pathology is dominated by coexistence of both perivenous and confluent white matter demyelination"
    explanation: >-
      This autopsy/biopsy cohort defines the mixed perivenous and confluent
      demyelinating lesion architecture characteristic of MOGAD.
  - reference: PMID:32412053
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most demyelinating lesions in 10 of 11 cases showed a perivenous
      demyelinating pattern previously reported in ADEM (153/167 lesions) and a
      fusion pattern (11/167 lesions)
    explanation: >-
      Independent brain-biopsy pathology confirms that perivenous demyelination
      is common across MOG antibody-associated disease lesions.
- name: CD4-positive T-cell and granulocytic inflammatory infiltrate
  description: >-
    Active MOGAD lesions show CD4-positive T-cell dominated inflammation with
    granulocytic infiltration, supporting a mixed cellular and humoral
    immunopathology rather than a classic MS plaque pattern.
  diagnostic: true
  context: Active CNS demyelinating lesions
  evidence:
  - reference: PMID:32048003
    reference_title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates."
    explanation: >-
      This directly supports CD4-positive T-cell dominant inflammatory
      infiltrates as a characteristic MOGAD lesion feature.
  - reference: PMID:32412053
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with CD4-dominance (CD4+ versus CD8+; 1281 ± 1196 cells/mm2 versus
      851 ± 762 cells/mm2, P < 0.01)
    explanation: >-
      Quantitative biopsy immunophenotyping supports CD4-positive T-cell
      predominance in MOG antibody-associated demyelinating lesions.
- name: Complement deposition in active white matter lesions
  description: >-
    Active MOGAD white matter lesions show complement deposition, consistent
    with humoral effector mechanisms contributing to myelin injury.
  diagnostic: true
  context: Active white matter lesions
  evidence:
  - reference: PMID:32048003
    reference_title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complement deposition is present in all active white matter lesions"
    explanation: >-
      Complement deposition in active lesions is a microscopic correlate of the
      complement-dependent effector mechanism modelled in pathophysiology.
- name: Preserved AQP4 without dystrophic astrocytes
  description: >-
    MOGAD lesions preserve aquaporin-4 expression and lack dystrophic
    astrocytes, distinguishing MOGAD pathology from AQP4-IgG-positive NMOSD
    astrocytopathy.
  diagnostic: true
  context: Differential neuropathology versus AQP4-IgG NMOSD
  evidence:
  - reference: PMID:32048003
    reference_title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AQP4 is preserved, with absence of dystrophic astrocytes"
    explanation: >-
      Astrocyte and AQP4 preservation supports MOGAD as pathologically distinct
      from AQP4-IgG NMOSD, where astrocytopathy is central.
phenotypes:
- name: Optic Neuritis
  description: >
    Inflammation of the optic nerve causing acute or subacute vision loss, eye
    pain (often worse with eye movement), and impaired color vision. In MOGAD
    optic neuritis is frequently bilateral, often with prominent optic disc
    edema/swelling at presentation, and tends to recur. MOGAD optic neuritis is
    a core clinical phenotype recognised by the international diagnostic
    criteria.
  category: Symptoms
  phenotype_term:
    preferred_term: optic neuritis
    term:
      id: HP:0100653
      label: Optic neuritis
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis"
    explanation: >
      Optic neuritis is one of the three core clinical phenotypes of MOGAD per
      the 2023 international diagnostic criteria.
  - reference: PMID:29695592
    reference_title: "Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical phenotype at onset included optic neuritis or myelitis in 90.86%"
    explanation: >
      In the MOGADOR adult cohort, optic neuritis or myelitis was the onset
      phenotype in over 90% of MOG-IgG-positive patients.
- name: Visual Loss
  description: >
    Acute or subacute visual acuity loss accompanying optic neuritis, ranging
    from blurred vision to no light perception. Visual recovery in MOGAD is
    generally better than in AQP4-IgG NMOSD, although severe deficits can
    accrue with relapses.
  category: Symptoms
  phenotype_term:
    preferred_term: visual loss
    term:
      id: HP:0000572
      label: Visual loss
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological disability accumulates with relapse and may manifest as visual, motor, sensory, and cognitive deficits."
    explanation: >
      Visual deficits are recognised as one of the major outcome domains in
      relapsing MOGAD; PARTIAL because the snippet refers to disability
      accrual rather than the acute visual loss phenotype itself.
- name: Optic Disc Swelling
  description: >
    Optic disc edema (papilledema-like appearance) is a frequent fundoscopic
    finding in MOGAD-associated optic neuritis and helps distinguish it from
    multiple sclerosis-associated optic neuritis, in which the disc is more
    often normal.
  category: Clinical Signs
  phenotype_term:
    preferred_term: optic disc edema
    term:
      id: HP:0001085
      label: Papilledema
  notes: >
    HPO does not have a separate term for "optic disc edema due to optic
    neuritis"; the closest standard label is HP:0001085 Papilledema.
  evidence:
  - reference: PMID:34418402
    reference_title: "Myelin-oligodendrocyte glycoprotein antibody-associated disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination."
    explanation: >
      Optic disc edema is a well-described imaging/fundoscopic feature of
      MOGAD optic neuritis. The cited Lancet Neurology overview supports
      MOGAD as a CNS demyelinating disease; the disc-edema specificity is
      established in the broader Marignier review body but not captured in
      the abstract, hence PARTIAL.
- name: Transverse Myelitis
  description: >
    Acute or subacute myelitis presenting with motor weakness (often
    paraparesis), sensory disturbance, and bladder/bowel dysfunction. MOGAD
    myelitis frequently involves the conus medullaris and may be longitudinally
    extensive (≥3 vertebral segments) on MRI, although shorter lesions also
    occur.
  category: Symptoms
  phenotype_term:
    preferred_term: transverse myelitis
    term:
      id: HP:0012486
      label: Myelitis
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis"
    explanation: >
      Transverse myelitis is one of the three core clinical phenotypes of
      MOGAD per the 2023 international diagnostic criteria.
- name: Spinal Cord Lesion
  description: >
    Inflammatory spinal cord MRI lesion underlying transverse myelitis. MOGAD
    spinal cord lesions are often longitudinally extensive, may involve the
    conus medullaris, and frequently show a central grey-matter "H-sign" on
    axial T2 sequences.
  category: Imaging
  phenotype_term:
    preferred_term: spinal cord lesion
    term:
      id: HP:0100561
      label: Spinal cord lesion
  evidence:
  - reference: PMID:34418402
    reference_title: "Myelin-oligodendrocyte glycoprotein antibody-associated disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination."
    explanation: >
      The Marignier et al. 2021 Lancet Neurology review establishes MOGAD as
      an inflammatory CNS demyelinating disease with characteristic spinal
      cord involvement.
- name: Acute Disseminated Encephalomyelitis
  description: >
    Multifocal CNS demyelinating syndrome with encephalopathy and multifocal
    neurological deficits, typically associated with extensive,
    poorly-demarcated, "fluffy" white-matter and deep grey-matter MRI lesions.
    ADEM is the most common MOGAD presentation in children and is frequently
    monophasic, although recurrent or multiphasic ADEM occurs.
  category: Symptoms
  phenotype_term:
    preferred_term: acute disseminated encephalomyelitis
    term:
      id: HP:0007305
      label: CNS demyelination
  notes: >
    HPO lacks a dedicated term for ADEM; the closest concept is HP:0007305
    CNS demyelination, with `preferred_term` capturing the specific
    syndrome name.
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis"
    explanation: >
      ADEM is one of the three core clinical phenotypes of MOGAD per the
      2023 international diagnostic criteria.
  - reference: PMID:30559466
    reference_title: "Myelin oligodendrocyte glycoprotein antibodies in neurological disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM)."
    explanation: >
      The Reindl and Waters 2019 review traces the original recognition of
      MOG-Abs in pediatric ADEM patients.
- name: Encephalopathy
  description: >
    Altered level of consciousness or cognition occurring with ADEM, cortical
    encephalitis, or brainstem involvement. Encephalopathy in childhood ADEM
    is a defining feature distinguishing it from a clinically isolated
    syndrome of MS.
  category: Symptoms
  phenotype_term:
    preferred_term: encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:29695592
    reference_title: "Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "isolated brainstem or encephalopathy syndromes in 6.6%"
    explanation: >
      Encephalopathy is recognised as an isolated onset phenotype in 6.6% of
      adult MOGAD patients in the MOGADOR cohort.
- name: Cerebral Cortical Encephalitis
  description: >
    A less common MOGAD presentation with seizures, headache, focal
    neurological deficits, and unilateral or bilateral cortical FLAIR
    hyperintensities. This phenotype overlaps with the so-called "FLAMES"
    presentation (FLAIR-hyperintense Lesions in Anti-MOG associated
    Encephalitis with Seizures).
  category: Symptoms
  phenotype_term:
    preferred_term: cerebral cortical encephalitis
    term:
      id: HP:0007305
      label: CNS demyelination
  notes: >
    HPO does not provide a non-infectious "cortical encephalitis" term and
    HP:0002383 Infectious encephalitis is semantically incorrect (autoimmune,
    not infectious). HP:0007305 CNS demyelination is used as the closest
    valid umbrella concept; `preferred_term` retains the specific clinical
    syndrome name. NTR for an HPO autoimmune cortical encephalitis term may
    be warranted.
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations"
    explanation: >
      Cerebral cortical encephalitis is recognised as a less common but
      bona fide MOGAD phenotype in the 2023 international criteria.
- name: Seizure
  description: >
    Focal or generalised seizures occurring in the context of cerebral
    cortical encephalitis or ADEM. Seizures are more common in MOGAD than in
    AQP4-IgG NMOSD or MS.
  category: Symptoms
  phenotype_term:
    preferred_term: seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:30559466
    reference_title: "Myelin oligodendrocyte glycoprotein antibodies in neurological disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes"
    explanation: >
      Seizures are recognised among the spectrum of MOG-Ab-associated
      neurological presentations in the Reindl and Waters 2019 review.
- name: Headache
  description: >
    Headache is a frequent presenting symptom of cerebral cortical encephalitis
    in MOGAD, often accompanying or preceding seizures and focal deficits.
  category: Symptoms
  phenotype_term:
    preferred_term: headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:30559466
    reference_title: "Myelin oligodendrocyte glycoprotein antibodies in neurological disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes"
    explanation: >
      Headache is a typical accompanying symptom of MOG-associated
      encephalitis presentations enumerated in this review; the snippet
      supports the encephalitis context but does not name headache
      explicitly, so PARTIAL.
- name: Brainstem Syndrome
  description: >
    Brainstem demyelinating lesions can produce diplopia, facial weakness,
    dysarthria, dysphagia, ataxia, or intractable nausea/vomiting and hiccups.
    Brainstem presentations are less common in MOGAD than in AQP4-IgG NMOSD
    but are recognised by the international diagnostic criteria.
  category: Symptoms
  phenotype_term:
    preferred_term: brainstem syndrome
    term:
      id: HP:0007305
      label: CNS demyelination
  notes: >
    HPO does not have a single term for "brainstem demyelinating syndrome";
    HP:0007305 CNS demyelination is used as the umbrella concept and the
    `preferred_term` provides the clinical specificity.
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations"
    explanation: >
      Brainstem presentations are explicitly listed as a recognised MOGAD
      phenotype in the 2023 international diagnostic criteria.
- name: Ataxia
  description: >
    Cerebellar or sensory ataxia can occur with brainstem and cerebellar MOGAD
    presentations, with patients showing gait instability and limb dysmetria.
  category: Symptoms
  phenotype_term:
    preferred_term: ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:36706773
    reference_title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations"
    explanation: >
      Brainstem and cerebellar presentations are recognised MOGAD
      phenotypes; ataxia is the dominant clinical sign of cerebellar
      involvement. Indirect support, hence PARTIAL.
- name: Paraparesis
  description: >
    Bilateral lower-limb weakness due to transverse myelitis, often presenting
    acutely or subacutely with sensory level and bladder dysfunction.
  category: Symptoms
  phenotype_term:
    preferred_term: paraparesis
    term:
      id: HP:0002385
      label: Paraparesis
  evidence:
  - reference: PMID:40088708
    reference_title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological disability accumulates with relapse and may manifest as visual, motor, sensory, and cognitive deficits."
    explanation: >
      Motor deficits in MOGAD are predominantly driven by transverse
      myelitis presenting as paraparesis. The snippet supports motor
      deficit accrual; PARTIAL because it does not name paraparesis
      specifically.
treatments:
- name: Acute Attack Treatment - High-Dose Corticosteroids
  description: >
    High-dose intravenous methylprednisolone (typically 1 g daily for 3-5
    days) is first-line therapy for acute MOGAD attacks. Many neurologists
    follow with a slow oral prednisone taper to reduce early relapse risk,
    given that abrupt steroid withdrawal in the months after an attack is
    associated with new attacks in MOGAD.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
  evidence:
  - reference: PMID:40708693
    reference_title: "Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute MOGAD attacks are generally responsive to high-dose corticosteroids"
    explanation: >
      The Wolf et al. 2023 review confirms high-dose corticosteroids as
      effective first-line acute attack therapy in MOGAD.
  - reference: PMID:40708693
    reference_title: "Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A slow corticosteroid taper may lower the risk of relapse."
    explanation: >
      Wolf et al. 2023 supports the practice of a slow steroid taper to
      mitigate early post-attack relapses in MOGAD.
- name: Acute Attack Treatment - Plasma Exchange
  description: >
    Therapeutic plasma exchange (plasmapheresis) is used for severe MOGAD
    attacks not responding to corticosteroids. Removes circulating MOG-IgG and
    other inflammatory mediators.
  treatment_term:
    preferred_term: plasmapheresis
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  target_mechanisms:
  - target: Anti-MOG Autoimmunity
    treatment_effect: INHIBITS
    description: >
      Plasma exchange physically removes circulating MOG-IgG, blunting the
      pathogenic autoantibody load.
  evidence:
  - reference: PMID:40708693
    reference_title: "Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "early use of plasma exchange or intravenous immunoglobulin may be beneficial for severe attacks or cases lacking corticosteroid response"
    explanation: >
      Wolf et al. 2023 review supports plasma exchange as escalation therapy
      for severe or steroid-refractory MOGAD attacks.
- name: Maintenance - Intravenous Immunoglobulin
  description: >
    Maintenance intravenous immunoglobulin (IVIG) is used in relapsing MOGAD,
    particularly in pediatric patients, with retrospective evidence suggesting
    favourable relapse-prevention compared to other immunosuppressants. Given
    typically every 3-4 weeks at maintenance dosing.
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: MAXO:0001480
      label: immunoglobulin infusion therapy
  target_mechanisms:
  - target: Anti-MOG Autoimmunity
    treatment_effect: INHIBITS
    description: >
      IVIG modulates pathogenic autoantibody activity through Fc-receptor
      saturation, complement scavenging, idiotype neutralisation, and
      immune-cell modulation, attenuating MOG-IgG-driven CNS injury.
  evidence:
  - reference: PMID:34634625
    reference_title: "Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mIVIG 25.3% [95%CI 14.0% to 41.3%; ARR 0.081 (0.058)]."
    explanation: >
      Meta-analysis of maintenance immunotherapies found the lowest pooled
      relapse probability and annualized relapse rate with maintenance IVIG.
  - reference: PMID:35377395
    reference_title: "Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median (range) annualized relapse rate before IVIG treatment was 1.4
      (0-6.1), compared with a median (range) annualized relapse rate while
      receiving IVIG of 0 (0-3)
    explanation: >
      Multicenter adult cohort data directly supports maintenance IVIG as a
      relapse-prevention therapy in MOGAD.
- name: Maintenance - Rituximab
  description: >
    Anti-CD20 monoclonal antibody used as maintenance therapy in relapsing
    MOGAD. Effectiveness is more modest than in AQP4-IgG NMOSD or MS, with
    relapses occurring even during apparent B-cell depletion in a substantial
    minority of patients.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Anti-MOG Autoimmunity
    treatment_effect: INHIBITS
    description: >
      Rituximab depletes CD20+ B cells, reducing the population of cells
      that can differentiate into MOG-IgG-producing antibody-secreting
      cells. Long-lived CD20-negative plasma cells likely explain
      incomplete efficacy.
  evidence:
  - reference: PMID:32629363
    reference_title: "Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion."
    explanation: >
      The Whittam et al. 2020 international study of 121 MOGAD patients
      demonstrated rituximab efficacy with limitations.
  - reference: PMID:32629363
    reference_title: "Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "RTX led to a 37% decline in relapse rate, and after 2 years, 33% of patients are predicted to remain relapse-free."
    explanation: >
      The treatment effect is partial - rituximab reduces but does not abolish
      MOGAD relapses, with only one-third remaining relapse-free at 2 years.
- name: Maintenance - Tocilizumab
  description: >
    Anti-IL-6 receptor monoclonal antibody used in rituximab-refractory or
    severely relapsing MOGAD. IL-6 is implicated in plasmablast survival and
    autoantibody production.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tocilizumab
      term:
        id: NCIT:C84217
        label: Tocilizumab
  target_mechanisms:
  - target: Anti-MOG Autoimmunity
    treatment_effect: INHIBITS
    description: >
      IL-6 receptor blockade reduces plasmablast survival and Th17/T-cell
      help that sustain MOG-IgG production.
  - target: Cognate T-Cell Mediated Inflammation
    treatment_effect: INHIBITS
    description: >
      IL-6 signalling drives Th17 differentiation and effector T-cell
      activation in CNS demyelinating disease; tocilizumab attenuates
      this arm of MOGAD pathophysiology.
  evidence:
  - reference: PMID:32629363
    reference_title: "Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tocilizumab (interleukin-6 blockade) has been used effectively in some patients with RTX-refractory MOGAD"
    explanation: >
      Tocilizumab is reported as an effective option in rituximab-refractory
      MOGAD in the Whittam et al. 2020 cohort discussion.
- name: Maintenance - Mycophenolate Mofetil
  description: >
    Oral immunosuppressant used as a steroid-sparing maintenance therapy in
    relapsing MOGAD, frequently in combination with low-dose oral prednisone.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: NCIT:C1468
        label: Mycophenolate Mofetil
  evidence:
  - reference: PMID:40708693
    reference_title: "Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Preventative treatment has been typically limited to patients with a definitive relapsing disease. While there is no consensus on the choice or duration of treatment, multiple therapies have been retrospectively evaluated."
    explanation: >
      MMF is one of the off-label maintenance therapies retrospectively
      evaluated in relapsing MOGAD; the Wolf et al. 2023 review summarises
      this evidence base. PARTIAL because the abstract does not call out
      MMF specifically.
- name: Maintenance - Azathioprine
  description: >
    Oral purine-analog immunosuppressant used as a steroid-sparing maintenance
    therapy in relapsing MOGAD. Often combined with low-dose oral prednisone
    until therapeutic effect is achieved.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azathioprine
      term:
        id: CHEBI:2948
        label: azathioprine
  evidence:
  - reference: PMID:40708693
    reference_title: "Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Preventative treatment has been typically limited to patients with a definitive relapsing disease. While there is no consensus on the choice or duration of treatment, multiple therapies have been retrospectively evaluated."
    explanation: >
      Azathioprine is among the off-label maintenance therapies
      retrospectively evaluated in relapsing MOGAD per the Wolf et al.
      2023 review. PARTIAL because the abstract does not call out
      azathioprine by name.
clinical_trials:
- name: NCT05271409
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Phase 3 randomized, double-blind trial evaluating satralizumab versus
    placebo, as monotherapy or added to baseline therapy, for prevention of
    adjudicated MOGAD relapse.
  evidence:
  - reference: clinicaltrials:NCT05271409
    reference_title: "A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main objective of this study is to evaluate the efficacy of
      satralizumab compared with placebo based on time from randomization to the
      first occurrence of an adjudicated MOGAD relapse in the double-blind (DB)
      treatment period.
    explanation: >-
      ClinicalTrials.gov documents an ongoing randomized phase 3 relapse
      prevention trial of satralizumab in MOGAD.
- name: NCT05063162
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 3 randomized, double-blind placebo-controlled pivotal trial with
    open-label extension evaluating rozanolixizumab in adults with MOGAD.
  evidence:
  - reference: clinicaltrials:NCT05063162
    reference_title: "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD)."  # codespell:ignore-line
    explanation: >-
      ClinicalTrials.gov documents a phase 3 FcRn-inhibition trial in adult
      MOGAD participants.
- name: NCT05349006
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Randomized placebo-controlled phase 3 trial testing azathioprine after a
    first MOGAD attack to prevent relapse and disability accrual.
  evidence:
  - reference: clinicaltrials:NCT05349006
    reference_title: "A Randomized, Placebo-controlled Phase 3 Trial of Azathioprine for the Prevention of Relapse in Myelin-oligodendrocyte-glycoprotein (MOG)-Antibody Associated Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The investigators propose herein the first randomized controlled trial in
      MOGAD, to evaluate the efficacy of azathioprine to prevent relapses,
      after a first attack, in a placebo double-blinded design.
    explanation: >-
      ClinicalTrials.gov documents a randomized phase 3 azathioprine relapse
      prevention trial in MOGAD.
- name: NCT06452537
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Randomized controlled multicenter phase 2/3 trial evaluating tocilizumab
    safety and efficacy in MOGAD.
  evidence:
  - reference: clinicaltrials:NCT06452537
    reference_title: "A Randomized, Controlled, Multicenter Study To Evaluate the Safety and Efficacy of Tocilizumab In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD."
    explanation: >-
      ClinicalTrials.gov documents an active randomized trial of IL-6 receptor
      blockade with tocilizumab in MOGAD.
datasets:
references:
- reference: PMID:36706773
  title: "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
- reference: PMID:34418402
  title: "Myelin-oligodendrocyte glycoprotein antibody-associated disease."
  findings: []
- reference: PMID:40088708
  title: "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis."
  findings: []
- reference: PMID:30559466
  title: "Myelin oligodendrocyte glycoprotein antibodies in neurological disease."
  findings: []
- reference: PMID:29695592
  title: "Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study."
  findings: []
- reference: PMID:32629363
  title: "Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients."
  findings: []
- reference: PMID:40708693
  title: "Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)."
  findings: []
- reference: PMID:41657079
  title: "MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
- reference: PMID:41865559
  title: "Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
- reference: PMID:32048003
  title: "The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
- reference: PMID:32412053
  title: "Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
- reference: PMID:34634625
  title: "Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
- reference: PMID:35377395
  title: "Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease."
  found_in:
  - MOGAD-deep-research-openscientist.md
  findings: []
📚

References & Deep Research

References

13
PMID:36706773
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
No top-level findings curated for this source.
PMID:34418402
Myelin-oligodendrocyte glycoprotein antibody-associated disease.
No top-level findings curated for this source.
PMID:40088708
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis.
No top-level findings curated for this source.
PMID:30559466
Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
No top-level findings curated for this source.
PMID:29695592
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
No top-level findings curated for this source.
PMID:32629363
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.
No top-level findings curated for this source.
PMID:40708693
Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
No top-level findings curated for this source.
PMID:41657079
MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology.
No top-level findings curated for this source.
PMID:41865559
Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.
No top-level findings curated for this source.
PMID:32048003
The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
No top-level findings curated for this source.
PMID:32412053
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
No top-level findings curated for this source.
PMID:34634625
Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder.
No top-level findings curated for this source.
PMID:35377395
Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
1. Disease Information
Edison Scientific Literature 45 citations 2026-05-03T17:36:05.472614

1. Disease Information

1.1 Overview (current understanding)

MOGAD is a rare, antibody-mediated inflammatory demyelinating disorder of the central nervous system (CNS) associated with serum (and sometimes CSF) MOG-IgG detected by cell-based assays, and is considered distinct from multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG neuromyelitis optica spectrum disorder (NMOSD). (voase2024diagnosticcriteriafor pages 1-2, alani2023myelinoligodendrocyteglycoprotein pages 3-4, jeyakumar2024mogantibodyassociatedoptic pages 1-2)

Direct abstract quote (definition/distinct entity): - Gklinos & Dobson (2024-05-xx) state: “Clinical syndromes associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) are now recognized as a distinct neurological disease entity…” (Antibodies; https://doi.org/10.3390/antib13020043) (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

1.2 Key identifiers and terminologies

  • Preferred name: Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). (alani2023myelinoligodendrocyteglycoprotein pages 3-4)
  • Common synonyms: MOG antibody disease; MOG-IgG–associated disease; MOG-IgG–associated disorder(s); MOG encephalomyelitis (legacy terminology). (alani2023myelinoligodendrocyteglycoprotein pages 3-4, forcadela2024timingofmogigg pages 1-2)
  • ICD/MeSH/Orphanet/OMIM codes: Not extractable from the retrieved evidence snippets in this run; a 2025 review notes existence of “unique international classification of diseases code (ICD-10-…)” but the code string was not present in accessible text. (NCT05271409 chunk 3)

1.3 Evidence provenance

Most knowledge summarized here is derived from aggregated disease-level resources (multi-center cohorts, registries, systematic reviews, consensus criteria, and clinical trial registries), not single-patient EHR-derived datasets. (alani2023myelinoligodendrocyteglycoprotein pages 3-4, forcadela2024timingofmogigg pages 1-2, varley2024validationofthe pages 1-2, NCT05063162 chunk 1, NCT05271409 chunk 1)

2. Etiology

2.1 Disease causal factors (mechanistic)

MOGAD is primarily an autoantibody-associated disease targeting MOG (a surface myelin/oligodendrocyte protein). Pathogenesis likely requires cooperation between humoral immunity (MOG-IgG) and cellular immune processes, as well as CNS barrier dysfunction permitting antibody/immune cell access. (abraham2024myelinoligodendrocyteantibody pages 10-13, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3, abraham2024myelinoligodendrocyteantibody pages 8-10)

2.2 Risk factors

Demographic risk context (not causal): disease occurs in both children and adults with a biphasic age distribution (see Epidemiology). (jeyakumar2024mogantibodyassociatedoptic pages 1-2)

Potential triggers (environment/infectious): initiating events proposed include infections leading to autoimmunity (molecular mimicry, bystander activation, polyclonal B-cell activation). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

Risk factors for relapsing course (prognostic): higher MOG-IgG titers and persistence of seropositivity are associated with relapsing disease; relapses cluster early and can follow steroid taper/cessation. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11, alani2023myelinoligodendrocyteglycoprotein pages 10-11)

2.3 Protective factors

Seroconversion to MOG-IgG negativity is associated with a lower relapse likelihood (e.g., ~90% likelihood of monophasic course in one 2024 review). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11)

2.4 Gene–environment interactions

No robust gene–environment interaction evidence was extractable from the retrieved sources in this run.

3. Phenotypes

3.1 Core clinical phenotypes (with frequency/characteristics)

MOGAD is defined by a compatible core demyelinating event, commonly including optic neuritis, myelitis, ADEM, brain/brainstem syndromes, and cortical encephalitis (often with seizures). (alani2023myelinoligodendrocyteglycoprotein pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10)

Optic neuritis (ON) - Frequency: most common initial adult manifestation ~30–60%. (jeyakumar2024mogantibodyassociatedoptic pages 1-2) - Common distinguishing features: bilateral involvement, disc swelling, longitudinally extensive optic nerve hyperintensity, optic perineuritis. (jeyakumar2024mogantibodyassociatedoptic pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10)

Transverse myelitis (TM) - Frequency: ~10–25% (one review) to ~30% (another review) in adults. (jeyakumar2024mogantibodyassociatedoptic pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 4-5) - Spinal cord features include LETM and gray-matter–predominant “H-sign” lesions; conus involvement is common. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)

Acute disseminated encephalomyelitis (ADEM) - Frequency: common in children, ~45% in children <11 years in one review; >50% in children <11 in another review. (jeyakumar2024mogantibodyassociatedoptic pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 4-5)

Cortical encephalitis / FLAMES - Reported phenotype characterized by unilateral cortical FLAIR hyperintensity and focal seizures that may generalize. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 3-4, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7)

3.2 Suggested HPO terms (examples; not exhaustive)

(Provided as ontology suggestions; not verified against HPO database during this run.) - Optic neuritis: HP:0000648 (Optic neuritis) - Visual impairment: HP:0000505 (Visual impairment) - Transverse myelitis / myelitis: HP:0002303 (Myelitis) / HP:0002375 (Transverse myelitis) - Paraparesis/quadriparesis: HP:0003401 (Paraparesis) / HP:0002376 (Quadriplegia) - Bladder dysfunction: HP:0000010 (Neurogenic bladder) - Seizures: HP:0001250 (Seizures) - Encephalopathy: HP:0001298 (Encephalopathy) - Headache: HP:0002315 (Headache)

3.3 Quality of life impact

Direct QoL instruments/results specific to MOGAD were not extractable from the obtained papers; however, relapse-driven disability is repeatedly emphasized, and QoL is an endpoint in ongoing interventional trials (e.g., EQ-5D-3L in NCT05349006). (NCT05349006 chunk 1)

4. Genetic/Molecular Information

4.1 Causal genes / inheritance

MOGAD is not established as a monogenic disorder; no causal germline variants were supported by retrieved evidence in this run. (alani2023myelinoligodendrocyteglycoprotein pages 3-4, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

4.2 Pathogenic variants, modifier genes, epigenetics

No validated pathogenic variants, modifier genes, or epigenetic drivers were extractable from the retrieved evidence in this run.

4.3 Molecular target

MOG is a CNS myelin/oligodendrocyte surface protein with an extracellular Ig-like domain that is immunogenic and accessible to antibodies. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

5. Environmental Information

5.1 Environmental/lifestyle factors

No specific toxins/pollution/lifestyle factors were supported by retrieved evidence in this run.

5.2 Infectious agents (triggering)

Infections are proposed triggers via immune activation/molecular mimicry; specific pathogen-level causality remains uncertain in the retrieved evidence. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

6. Mechanism / Pathophysiology

6.1 Causal chain (current model)

A convergent contemporary model is: 1) Peripheral activation of MOG-reactive B cells/plasma cells (sometimes after systemic inflammation/infection) → generation of MOG-IgG (often IgG1). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3, abraham2024myelinoligodendrocyteantibody pages 29-31) 2) CNS barrier dysfunction (BBB/blood–CSF barrier) enables entry of MOG-IgG and immune cells. (abraham2024myelinoligodendrocyteantibody pages 8-10, abraham2024myelinoligodendrocyteantibody pages 5-8) 3) Antibody binds conformational extracellular epitopes of MOG on myelin/oligodendrocytes and triggers effector mechanisms including complement activation, ADCC/ADCP, and downstream oligodendrocyte signaling/cytoskeletal disruption → inflammatory demyelination with perivenous/confluent lesion architecture. (abraham2024myelinoligodendrocyteantibody pages 10-13, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3, abraham2024myelinoligodendrocyteantibody pages 5-8, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 3-4) 4) Clinical manifestations depend on site of demyelination (optic nerve, spinal cord, brain/cortex). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7)

6.2 Key pathways and processes

  • Complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP) are described as candidate effector mechanisms. (abraham2024myelinoligodendrocyteantibody pages 10-13, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)
  • Intracellular signaling perturbations in oligodendrocytes (e.g., MAPK/AKT) and cytoskeletal disruption are described as possible downstream mechanisms. (abraham2024myelinoligodendrocyteantibody pages 10-13)

6.3 Suggested GO biological process terms (examples)

(Ontology suggestions; not database-validated in this run.) - GO:0006955 immune response - GO:0006954 inflammatory response - GO:0002443 leukocyte mediated immunity - GO:0002250 adaptive immune response - GO:0002252 immune effector process - GO:0002479 antigen processing and presentation - GO:0002526 acute inflammatory response - GO:0006935 chemotaxis (for recruited myeloid cells) - GO:0006898 receptor-mediated endocytosis / phagocytosis-related terms (for ADCP)

6.4 Cell types involved (suggested CL terms)

(Ontology suggestions; not database-validated in this run.) - Oligodendrocyte: CL:0000128 - Microglia: CL:0000129 - Macrophage: CL:0000235 - CD4-positive T cell: CL:0000624 - B cell / plasma cell: CL:0000236 / CL:0000786

7. Anatomical Structures Affected

7.1 Organ and system level

Primary: central nervous system—optic nerves, spinal cord, brain (including cortex in FLAMES), brainstem/cerebellar pathways. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7)

7.2 Suggested UBERON terms (examples)

(Ontology suggestions; not database-validated in this run.) - Optic nerve: UBERON:0000940 - Spinal cord: UBERON:0002240 - Brain: UBERON:0000955 - Cerebral cortex: UBERON:0000956

7.3 Subcellular localization

Pathogenic binding occurs at the cell surface of myelin/oligodendrocytes (MOG is on outermost myelin). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

8. Temporal Development

8.1 Onset

MOGAD can present in childhood or adulthood with acute/subacute demyelinating attacks; age distribution is biphasic (5–10 years; 20–45 years). (jeyakumar2024mogantibodyassociatedoptic pages 1-2)

8.2 Progression and course

MOGAD can be monophasic or relapsing; a 2024 review summarized ~65% monophasic and ~35% relapsing. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10)

Relapses tend to occur early (often within 6–12 months) and are frequently temporally associated with steroid taper/cessation. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11, wolf2023emergingprinciplesfor pages 4-6)

9. Inheritance and Population

9.1 Epidemiology (recent estimates)

From a 2024 neuro-ophthalmology review: - Annual incidence: ~1.6–4.8 per million - Prevalence: ~1.3–2.5 per 100,000 - Biphasic age peaks: 5–10 years and 20–45 years; median onset ~20–30 years - Sex ratio: approximately F:M 1:1 (with another review suggesting slight female predominance ~1.5:1). (jeyakumar2024mogantibodyassociatedoptic pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)

10. Diagnostics

10.1 Diagnostic criteria (2023 International MOGAD Panel)

Multiple 2024 validation studies and reviews summarize a three-step diagnostic logic: 1) Identify a core clinical demyelinating event (e.g., ON, TM, ADEM, brain/brainstem/cerebellar syndrome, cortical encephalitis with seizures). (alani2023myelinoligodendrocyteglycoprotein pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10) 2) Demonstrate MOG-IgG positivity (preferably in serum) using a cell-based assay, ideally a live CBA using full-length human MOG. (alani2023myelinoligodendrocyteglycoprotein pages 3-4, forcadela2024timingofmogigg pages 1-2) 3) Exclude alternative diagnoses (especially MS and AQP4-IgG NMOSD). (voase2024diagnosticcriteriafor pages 1-2, forcadela2024timingofmogigg pages 1-2)

Low-positive or ambiguous serology requires supportive clinical/MRI evidence. (alani2023myelinoligodendrocyteglycoprotein pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10)

A cropped table from a 2023 review that reproduces the criteria is provided in the evidence base. (alani2023myelinoligodendrocyteglycoprotein media 796e2466)

10.2 Assay methodology and interpretation (titer/PPV)

  • Cell-based assays are emphasized; ELISA is discouraged due to lower specificity and discordance. (alani2023myelinoligodendrocyteglycoprotein pages 3-4)
  • PPV varies strongly by titer and by testing population. One 2024 study reported PPV of MOG-IgG “at any time” 78.3% overall, 52.6% for low titer, 90.1% for high titer, and much higher PPV in children vs adults. (varley2024validationofthe pages 1-2)
  • Reviews summarize that low titers can generate false positives and require careful clinical/MRI correlation. (alani2023myelinoligodendrocyteglycoprotein pages 3-4, rechtman2024assessingtheapplicability pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)

10.3 Supportive MRI/CSF features

Supportive imaging features (particularly important for low-positive results) include: bilateral ON, >50% optic nerve involvement, optic disc edema, optic perineuritis; LETM, central cord/H-sign, conus involvement; fluffy, poorly demarcated deep gray/cortical/brainstem lesions. (alani2023myelinoligodendrocyteglycoprotein pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)

CSF: pleocytosis and elevated protein in ~50%; oligoclonal bands uncommon (<10–15%). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)

10.4 Diagnostic accuracy and validation (2024)

  • Varley et al. (Neurology; 2024-07) reported high performance of the 2023 criteria in a selected cohort: sensitivity 96.5%, specificity 98.9%, PPV 94.3%, NPV 99.3%, accuracy 98.5%. (https://doi.org/10.1212/WNL.0000000000209321) (varley2024validationofthe pages 1-2)
  • Forcadela et al. (NNI; 2024-01) emphasized timing: low-positive results correlate with delayed sampling and criteria can miss cases if testing is delayed or investigations are incomplete; they report sensitivity 97% and specificity 100% in their cohort. (https://doi.org/10.1212/nxi.0000000000200183) (forcadela2024timingofmogigg pages 1-2)

11. Outcome / Prognosis

11.1 Disability and relapse contribution

Reviews emphasize that relapses are a major driver of disability and that predicting relapse at diagnosis remains difficult; persistent seropositivity and high titers support higher relapse risk. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11, alani2023myelinoligodendrocyteglycoprotein pages 10-11)

11.2 Prognostic biomarkers (candidate)

A 2024 review summarizes multiple candidate predictors (none fully validated): persistent seropositivity at 3 months, higher titers, certain epitope specificities, CSF protein/leukocytes, PLR, serum neurofilament light chain, polyphasic first attack, comorbid immunologic disease. (abraham2024myelinoligodendrocyteantibody pages 27-29)

12. Treatment

12.1 Acute relapse treatment (real-world implementation)

Corticosteroids are first-line and MOGAD attacks are typically highly steroid responsive; an extended taper is commonly used to mitigate early relapse risk. (alani2023myelinoligodendrocyteglycoprotein pages 9-10, wolf2023emergingprinciplesfor pages 4-6)

Quantitative observational outcomes: - A retrospective dataset summarized in Wolf et al. (2023-11) reported outcomes after IVMP across 122 relapses: 50% complete/nearly complete recovery, 44.3% partial recovery, 7% minimal/no recovery. (https://doi.org/10.1007/s11940-023-00776-1) (wolf2023emergingprinciplesfor pages 3-4) - A review summarized a retrospective comparison with response rates 96% IVMP, 90% PLEX, 91% IVIG. (abraham2024myelinoligodendrocyteantibody pages 17-20)

Second-line/adjunct in refractory or severe attacks: plasma exchange (PLEX) and IVIG. (wolf2023emergingprinciplesfor pages 3-4)

12.2 Maintenance (relapse prevention; off-label practice)

Commonly considered after ≥2 attacks, with some experts considering earlier in severe poor-recovery cases. (wolf2023emergingprinciplesfor pages 4-6)

Evidence synthesis (observational): - IVIG: multicenter cohort summarized by Wolf et al. shows ARR reduction 1.4 → 0.39; relapse occurred in 34% overall but 17% with ≥1 g/kg every 4 weeks; only 3% discontinued due to adverse events. (wolf2023emergingprinciplesfor pages 6-8) - Azathioprine (AZA) / Mycophenolate mofetil (MMF): may reduce ARR in some retrospective series but up to ~50% relapse; delayed onset (3–6 months) often requires bridging with steroids; notable safety monitoring needs (e.g., TPMT testing for AZA). (wolf2023emergingprinciplesfor pages 6-8, wolf2023emergingprinciplesfor pages 4-6) - Rituximab (anti-CD20): meta-analytic support for ARR reduction, but potentially less effective than in AQP4+ NMOSD; relapses may occur without link to B-cell repletion. (wolf2023emergingprinciplesfor pages 6-8) - IL-6 receptor blockade (tocilizumab/satralizumab): biologically plausible with supportive retrospective series; Wolf et al. note retrospective series with relapse reduction and report (largest series) 73% relapse-free >1 year. (wolf2023emergingprinciplesfor pages 8-9) - FcRn inhibition (rozanolixizumab): rationale is reducing pathogenic IgG by blocking FcRn-mediated IgG recycling; now being tested in phase 3. (wolf2023emergingprinciplesfor pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 11-13)

12.3 Treatment ontology suggestions (MAXO; examples)

(Ontology suggestions; not database-validated in this run.) - High-dose corticosteroid therapy: MAXO term for systemic glucocorticoid therapy - Plasma exchange: MAXO term for therapeutic plasma exchange - Intravenous immunoglobulin therapy: MAXO term for IVIG administration - Anti-CD20 monoclonal antibody therapy (rituximab) - Immunosuppressive therapy (azathioprine, mycophenolate) - Anti–IL-6 receptor therapy (tocilizumab, satralizumab) - FcRn inhibitor therapy (rozanolixizumab)

13. Prevention

No established primary prevention exists; secondary/tertiary prevention focuses on: - Accurate diagnosis (avoid false positives/overdiagnosis due to low titers and non-specific testing). (alani2023myelinoligodendrocyteglycoprotein pages 3-4, varley2024validationofthe pages 1-2, rechtman2024assessingtheapplicability pages 1-2) - Relapse prevention using prolonged steroid taper and/or maintenance immunotherapy in relapsing disease. (wolf2023emergingprinciplesfor pages 4-6, wolf2023emergingprinciplesfor pages 6-8)

14. Other Species / Natural Disease

No naturally occurring veterinary MOGAD analog evidence was retrieved in this run.

15. Model Organisms

Mechanistic work includes animal model evidence that anti-MOG antibodies can be pathogenic in the presence of myelin-reactive T cells; translation is complicated because many human MOG antibodies do not bind rodent MOG. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3)

Recent developments (2023–2024 emphasis)

1) Formal diagnostic criteria (2023) and real-world validation (2024): Multiple 2024 studies report high sensitivity/specificity and highlight timing and supportive-feature requirements for low-positive titers. (forcadela2024timingofmogigg pages 1-2, varley2024validationofthe pages 1-2, rechtman2024assessingtheapplicability pages 1-2) 2) Quantitative emphasis on test interpretation: 2024 PPV analysis shows marked drop in PPV for low titers and for patients lacking a core demyelinating attack. (varley2024validationofthe pages 1-2) 3) Shift toward targeted relapse-prevention trials: Phase 3 trials are actively evaluating FcRn inhibition (rozanolixizumab) and IL-6 blockade (satralizumab); a phase 3 immunosuppressant strategy trial (azathioprine) and a randomized tocilizumab trial are ongoing. (NCT05063162 chunk 1, NCT05271409 chunk 1, NCT05349006 chunk 1, NCT06452537 chunk 1)

Current applications and real-world implementations

  • Standard of care in most centers uses high-dose steroids for acute attacks, early escalation to IVIG/PLEX if poor response, and individualized relapse-prevention therapy (often IVIG, AZA/MMF, rituximab, with increasing interest in IL-6 blockade). (wolf2023emergingprinciplesfor pages 3-4, wolf2023emergingprinciplesfor pages 6-8, wolf2023emergingprinciplesfor pages 8-9)
  • Monitoring: serial MOG-IgG titers are sometimes followed; seronegativity by ~12 months is associated with monophasic course in one review (but later re-positivity can occur). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11)

Expert opinion / analysis (authoritative sources)

  • Diagnostic caution is repeatedly stressed: testing is meaningful only with compatible phenotype and imaging, and low titers require careful weighting because PPV depends on pretest probability and population prevalence. (alani2023myelinoligodendrocyteglycoprotein pages 3-4, varley2024validationofthe pages 1-2)
  • Treatment evidence remains dominated by retrospective cohorts; expert reviews emphasize the urgent need for RCTs and biomarkers to guide long-term immunotherapy decisions. (wolf2023emergingprinciplesfor pages 8-9, abraham2024myelinoligodendrocyteantibody pages 20-22)

Key statistics (selected)

  • Incidence: 1.6–4.8 per million/year; prevalence: 1.3–2.5 per 100,000. (jeyakumar2024mogantibodyassociatedoptic pages 1-2)
  • Biphasic age peaks: 5–10 years and 20–45 years; median onset ~20–30 years. (jeyakumar2024mogantibodyassociatedoptic pages 1-2)
  • Course: ~65% monophasic / 35% relapsing (review summary). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10)
  • CSF: pleocytosis ~50%; oligoclonal bands <10–15%. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)
  • Diagnostic criteria validation (2024): sensitivity 96.5%, specificity 98.9% (selected cohort). (varley2024validationofthe pages 1-2)
  • Acute IVMP outcomes (retrospective): 50% complete/nearly complete recovery, 44.3% partial, 7% minimal/no recovery. (wolf2023emergingprinciplesfor pages 3-4)
  • IVIG maintenance (multicenter cohort summary): ARR 1.4 → 0.39; relapse on IVIG 34% overall, 17% with ≥1 g/kg q4w; AE discontinuation 3%. (wolf2023emergingprinciplesfor pages 6-8)

Visual evidence: 2023 criteria table

A cropped table summarizing the 2023 International MOGAD Panel diagnostic criteria (core clinical events, titer thresholds, and supportive features) is available from Al-Ani et al. (2023). (alani2023myelinoligodendrocyteglycoprotein media 796e2466)

Structured summary artifact

Domain Key points Key citations
Definition/IDs • MOGAD = myelin oligodendrocyte glycoprotein antibody-associated disease, a distinct autoimmune inflammatory demyelinating CNS disorder recognized as separate from MS and AQP4-NMOSD. • 2023 international criteria use a 3-step framework: (1) core clinical demyelinating event, (2) positive serum MOG-IgG by cell-based assay, (3) exclusion of a better diagnosis. • Recommended serology: full-length human MOG cell-based assay; live CBA preferred/most specific in reviews. (voase2024diagnosticcriteriafor pages 1-2, alani2023myelinoligodendrocyteglycoprotein pages 3-4, varley2024validationofthe pages 1-2)
Core phenotypes • Adults: optic neuritis is most common initial phenotype (~30–60%; ~50% in some adult cohorts), transverse myelitis ~10–30%. • Children: ADEM is common, especially age <11 years (~45% to >50% initial presentations); cortical encephalitis/FLAMES with seizures is a recognized phenotype. • Disease course may be monophasic or relapsing; one 2024 review summarizes ~65% monophasic and ~35% relapsing overall. (jeyakumar2024mogantibodyassociatedoptic pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 4-5, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 3-4)
Diagnostics • 2023 criteria: clear-positive serum titer ≥1:100 on fixed CBA can support diagnosis without extra supportive features; low-positive titers ≥1:10 and <1:100 require AQP4-IgG negativity plus ≥1 supporting clinical/MRI feature. • Supportive MRI features: ON—bilateral simultaneous involvement, >50% optic nerve length involvement, optic disc edema, perineural sheath enhancement; myelitis—LETM, central/H-sign lesion, conus lesion; brain—fluffy deep gray/brainstem/cortical lesions. • PPV of MOG-IgG testing varies by titer and population: overall 78.3%; low titer 52.6%; high titer 90.1%; live CBA PPV reported ~51% at 1:20–1:40, 82% at 1:100, 100% at 1:1000; low-positive results and delayed sampling need caution. (alani2023myelinoligodendrocyteglycoprotein pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, alani2023myelinoligodendrocyteglycoprotein pages 3-4, forcadela2024timingofmogigg pages 1-2, varley2024validationofthe pages 1-2)
Epidemiology • Annual incidence ~1.6–4.8 per million; prevalence ~1.3–2.5 per 100,000. • Age is biphasic: peaks at 5–10 years and 20–45 years; median onset ~20–30 years. • Sex ratio is near equal in one 2024 review (F:M ~1:1), though another review notes slight female predominance (~1.5:1). (jeyakumar2024mogantibodyassociatedoptic pages 1-2, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)
Pathophysiology • Target antigen MOG is on the outermost myelin/oligodendrocyte surface; pathogenic MOG-IgG1 binds conformational extracellular epitopes. • Proposed mechanism: peripheral B-cell/antibody response + T-cell cooperation, BBB disruption, then antibody-mediated injury via complement-dependent cytotoxicity, ADCC, ADCP/opsonization and oligodendrocyte signaling/cytoskeletal disruption. • Pathology often shows perivenous/confluent demyelination, gray + white matter involvement, CD4+/granulocytic inflammation, relative astrocyte sparing, and frequent remyelination/shrinking lesions after attacks. (abraham2024myelinoligodendrocyteantibody pages 10-13, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3, abraham2024myelinoligodendrocyteantibody pages 1-5, abraham2024myelinoligodendrocyteantibody pages 5-8, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 3-4)
Key MRI/CSF findings • Optic neuritis MRI: bilateral/anterior optic pathway involvement, enhancement in almost all ON cases, often extending >50% of nerve length; optic perineuritis and disc edema are characteristic. • Spinal MRI: LETM common, but >50% of spinal lesions may be short; gray-matter-predominant H-sign and conus involvement are typical. • CSF: pleocytosis in ~50%, elevated protein in ~50%, oligoclonal bands uncommon (<10–15%). (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8)
Prognosis/relapse predictors • Persistent MOG-IgG seropositivity and high titers predict relapsing course; seroconversion to negativity by 12 months is associated with ~90% likelihood of a monophasic course/90% NPV for relapse. • Relapses cluster in first 6–12 months and often follow steroid taper/cessation; early relapse within 12 months raises future relapse risk. • Other reported risk factors: initial TM or encephalitis, incomplete recovery, higher CSF protein/leukocytes, polyphasic first attack, higher PLR/sNfL; prediction remains imperfect. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11, alani2023myelinoligodendrocyteglycoprotein pages 10-11, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 11-13, abraham2024myelinoligodendrocyteantibody pages 27-29)
Acute treatment • First-line: high-dose corticosteroids (commonly IV methylprednisolone ~1 g/day for 3–5 days), usually followed by prolonged taper; attacks are typically highly steroid responsive. • Retrospective data: IVMP complete/nearly complete recovery 50%, partial 44.3%, minimal/no recovery 7%; another comparison reported response rates 96% IVMP, 90% PLEX, 91% IVIG. • PLEX/IVIG used for steroid-refractory or severe attacks; in one multicenter ON series treated with PLEX, significant improvement occurred in nearly all cases. (alani2023myelinoligodendrocyteglycoprotein pages 9-10, wolf2023emergingprinciplesfor pages 3-4, abraham2024myelinoligodendrocyteantibody pages 17-20)
Maintenance treatment • Usually considered after ≥2 attacks; extended oral steroid taper lowers early relapse risk, and most relapses occur within 2 months of steroid cessation. • IVIG has strongest observational support: multicenter cohort ARR 1.4 to 0.39; relapse on IVIG 34% overall but 17% with ≥1 g/kg every 4 weeks; another review summarizes ~70% remission/majority relapse-free. • Off-label steroid-sparing agents have mixed efficacy: rituximab ~50% relapse-free in one review; mycophenolate ~47%; azathioprine ~39%; IL-6 blockers show promise, with a retrospective tocilizumab series reporting 73% relapse-free >1 year. (wolf2023emergingprinciplesfor pages 6-8, wolf2023emergingprinciplesfor pages 8-9, gklinos2024myelinoligodendrocyteglycoproteinantibody pages 11-13, abraham2024myelinoligodendrocyteantibody pages 20-22, wolf2023emergingprinciplesfor pages 4-6)
Trials • Satralizumab METEOROID (NCT05271409): Phase 3, randomized double-blind placebo-controlled, recruiting, n≈152; primary endpoint time to first adjudicated relapse. • Rozanolixizumab cosMOG (NCT05063162): Phase 3, randomized double-blind with OLE, active not recruiting, enrolled 113; primary endpoint time to first centrally adjudicated relapse. • Azathioprine in MOGAD (NCT05349006): Phase 3, placebo-controlled, recruiting, n=126, first-attack adults; Tocilizumab trial (NCT06452537): Phase 2/3, randomized open-label, active not recruiting, n≈102; primary endpoint time to first adjudicated relapse. (NCT05271409 chunk 1, NCT05063162 chunk 1, NCT05349006 chunk 1, NCT06452537 chunk 1)

Table: This table condenses high-yield disease characteristics of MOGAD for knowledge-base use, including 2023 diagnostic criteria, major phenotypes, epidemiology, pathophysiology, treatment evidence, and ongoing interventional trials.

Ongoing interventional trials (ClinicalTrials.gov; real-world implementation pipeline)

  • NCT05271409 (METEOROID; satralizumab) – Phase 3, randomized double-blind placebo-controlled, recruiting; primary endpoint: time to first adjudicated relapse; estimated n≈152; ages ≥12. (Record sponsor: Hoffmann-La Roche; start 2022; URL: https://clinicaltrials.gov/study/NCT05271409) (NCT05271409 chunk 1)
  • NCT05063162 (cosMOG; rozanolixizumab) – Phase 3, randomized double-blind with open-label extension; ACTIVE_NOT_RECRUITING; enrolled 113; primary endpoint: time to first centrally adjudicated relapse. (Sponsor: UCB Biopharma SRL; start 2022-02-02; URL: https://clinicaltrials.gov/study/NCT05063162) (NCT05063162 chunk 1)
  • NCT05349006 (Azathioprine in MOGAD) – Phase 3, placebo-controlled, recruiting; first-attack adults; primary endpoint: time to first relapse up to 3 years; includes EQ-5D-3L QoL endpoint. (Sponsor: Hospices Civils de Lyon; start 2023-12-12; URL: https://clinicaltrials.gov/study/NCT05349006) (NCT05349006 chunk 1)
  • NCT06452537 (Tocilizumab in MOGAD) – Phase 2/3, randomized open-label, ACTIVE_NOT_RECRUITING; n≈102; primary endpoint: time to first adjudicated relapse. (Sponsor: Tianjin Medical University General Hospital; start 2024-07-09; URL: https://clinicaltrials.gov/study/NCT06452537) (NCT06452537 chunk 1)

Limitations of this report (data availability)

  • ICD/MeSH/Orphanet/OMIM identifiers and PMIDs were not directly retrievable from the tool-accessible snippets, so these could not be exhaustively enumerated. (NCT05271409 chunk 3)
  • Several mechanistic/pathology statements are based on 2024 narrative reviews (including one with incomplete bibliographic metadata in the retrieved record), and should be cross-checked against primary pathology papers for formal knowledge-base curation. (abraham2024myelinoligodendrocyteantibody pages 10-13, abraham2024myelinoligodendrocyteantibody pages 1-5)

References

  1. (voase2024diagnosticcriteriafor pages 1-2): Sophie Voase and Neil P. Robertson. Diagnostic criteria for mogad. Journal of Neurology, 271:3690-3692, May 2024. URL: https://doi.org/10.1007/s00415-024-12405-1, doi:10.1007/s00415-024-12405-1. This article has 4 citations and is from a domain leading peer-reviewed journal.

  2. (alani2023myelinoligodendrocyteglycoprotein pages 3-4): Abdullah Al-Ani, John J. Chen, and Fiona Costello. Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad): current understanding and challenges. Journal of Neurology, 270:1-19, May 2023. URL: https://doi.org/10.1007/s00415-023-11737-8, doi:10.1007/s00415-023-11737-8. This article has 72 citations and is from a domain leading peer-reviewed journal.

  3. (jeyakumar2024mogantibodyassociatedoptic pages 1-2): Niroshan Jeyakumar, Magdalena Lerch, Russell C. Dale, and Sudarshini Ramanathan. Mog antibody-associated optic neuritis. Eye, 38:2289-2301, May 2024. URL: https://doi.org/10.1038/s41433-024-03108-y, doi:10.1038/s41433-024-03108-y. This article has 67 citations and is from a peer-reviewed journal.

  4. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 1-3): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  5. (forcadela2024timingofmogigg pages 1-2): Mirasol Forcadela, Chiara Rocchi, Daniel San Martin, Emily L. Gibbons, Daniel Wells, Mark R. Woodhall, Patrick J. Waters, Saif Huda, and Shahd Hamid. Timing of mog-igg testing is key to 2023 mogad diagnostic criteria. Neurology Neuroimmunology & Neuroinflammation, Jan 2024. URL: https://doi.org/10.1212/nxi.0000000000200183, doi:10.1212/nxi.0000000000200183. This article has 54 citations.

  6. (NCT05271409 chunk 3): A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. Hoffmann-La Roche. 2022. ClinicalTrials.gov Identifier: NCT05271409

  7. (varley2024validationofthe pages 1-2): James A. Varley, Dimitrios Champsas, Timothy Prossor, Giuseppe Pontillo, Omar Abdel-Mannan, Zhaleh Khaleeli, Axel Petzold, Ahmed T. Toosy, Sachid A. Trip, Heather Wilson, Dermot H. Mallon, Cheryl Hemingway, Kshitij Mankad, Michael Kin Loon Chou, Andrew J. Church, Melanie S. Hart, Michael P. Lunn, Wallace Brownlee, Yael Hacohen, and Olga Ciccarelli. Validation of the 2023 international diagnostic criteria for mogad in a selected cohort of adults and children. Neurology, Jul 2024. URL: https://doi.org/10.1212/wnl.0000000000209321, doi:10.1212/wnl.0000000000209321. This article has 33 citations and is from a highest quality peer-reviewed journal.

  8. (NCT05063162 chunk 1): A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD). UCB Biopharma SRL. 2022. ClinicalTrials.gov Identifier: NCT05063162

  9. (NCT05271409 chunk 1): A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. Hoffmann-La Roche. 2022. ClinicalTrials.gov Identifier: NCT05271409

  10. (abraham2024myelinoligodendrocyteantibody pages 10-13): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  11. (abraham2024myelinoligodendrocyteantibody pages 8-10): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  12. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 10-11): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  13. (alani2023myelinoligodendrocyteglycoprotein pages 10-11): Abdullah Al-Ani, John J. Chen, and Fiona Costello. Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad): current understanding and challenges. Journal of Neurology, 270:1-19, May 2023. URL: https://doi.org/10.1007/s00415-023-11737-8, doi:10.1007/s00415-023-11737-8. This article has 72 citations and is from a domain leading peer-reviewed journal.

  14. (alani2023myelinoligodendrocyteglycoprotein pages 8-9): Abdullah Al-Ani, John J. Chen, and Fiona Costello. Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad): current understanding and challenges. Journal of Neurology, 270:1-19, May 2023. URL: https://doi.org/10.1007/s00415-023-11737-8, doi:10.1007/s00415-023-11737-8. This article has 72 citations and is from a domain leading peer-reviewed journal.

  15. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 8-10): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  16. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 4-5): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  17. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 5-7): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  18. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 7-8): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  19. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 3-4): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  20. (NCT05349006 chunk 1): Azathioprine in MOGAD. Hospices Civils de Lyon. 2023. ClinicalTrials.gov Identifier: NCT05349006

  21. (abraham2024myelinoligodendrocyteantibody pages 29-31): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  22. (abraham2024myelinoligodendrocyteantibody pages 5-8): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  23. (wolf2023emergingprinciplesfor pages 4-6): Andrew B. Wolf, Jacqueline Palace, and Jeffrey L. Bennett. Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). Current Treatment Options in Neurology, 25:437-453, Nov 2023. URL: https://doi.org/10.1007/s11940-023-00776-1, doi:10.1007/s11940-023-00776-1. This article has 5 citations and is from a peer-reviewed journal.

  24. (alani2023myelinoligodendrocyteglycoprotein media 796e2466): Abdullah Al-Ani, John J. Chen, and Fiona Costello. Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad): current understanding and challenges. Journal of Neurology, 270:1-19, May 2023. URL: https://doi.org/10.1007/s00415-023-11737-8, doi:10.1007/s00415-023-11737-8. This article has 72 citations and is from a domain leading peer-reviewed journal.

  25. (rechtman2024assessingtheapplicability pages 1-2): Ariel Rechtman, Tal Freidman-Korn, Omri Zveik, Lyne Shweiki, Garrick Hoichman, and Adi Vaknin-Dembinsky. Assessing the applicability of the 2023 international mogad panel criteria in real-world clinical settings. Journal of Neurology, 271:5102-5108, May 2024. URL: https://doi.org/10.1007/s00415-024-12438-6, doi:10.1007/s00415-024-12438-6. This article has 10 citations and is from a domain leading peer-reviewed journal.

  26. (abraham2024myelinoligodendrocyteantibody pages 27-29): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  27. (alani2023myelinoligodendrocyteglycoprotein pages 9-10): Abdullah Al-Ani, John J. Chen, and Fiona Costello. Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad): current understanding and challenges. Journal of Neurology, 270:1-19, May 2023. URL: https://doi.org/10.1007/s00415-023-11737-8, doi:10.1007/s00415-023-11737-8. This article has 72 citations and is from a domain leading peer-reviewed journal.

  28. (wolf2023emergingprinciplesfor pages 3-4): Andrew B. Wolf, Jacqueline Palace, and Jeffrey L. Bennett. Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). Current Treatment Options in Neurology, 25:437-453, Nov 2023. URL: https://doi.org/10.1007/s11940-023-00776-1, doi:10.1007/s11940-023-00776-1. This article has 5 citations and is from a peer-reviewed journal.

  29. (abraham2024myelinoligodendrocyteantibody pages 17-20): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  30. (wolf2023emergingprinciplesfor pages 6-8): Andrew B. Wolf, Jacqueline Palace, and Jeffrey L. Bennett. Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). Current Treatment Options in Neurology, 25:437-453, Nov 2023. URL: https://doi.org/10.1007/s11940-023-00776-1, doi:10.1007/s11940-023-00776-1. This article has 5 citations and is from a peer-reviewed journal.

  31. (wolf2023emergingprinciplesfor pages 8-9): Andrew B. Wolf, Jacqueline Palace, and Jeffrey L. Bennett. Emerging principles for treating myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). Current Treatment Options in Neurology, 25:437-453, Nov 2023. URL: https://doi.org/10.1007/s11940-023-00776-1, doi:10.1007/s11940-023-00776-1. This article has 5 citations and is from a peer-reviewed journal.

  32. (gklinos2024myelinoligodendrocyteglycoproteinantibody pages 11-13): Panagiotis Gklinos and Ruth Dobson. Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies, 13:43, May 2024. URL: https://doi.org/10.3390/antib13020043, doi:10.3390/antib13020043. This article has 24 citations.

  33. (NCT06452537 chunk 1): Chao Zhang. Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. Tianjin Medical University General Hospital. 2024. ClinicalTrials.gov Identifier: NCT06452537

  34. (abraham2024myelinoligodendrocyteantibody pages 20-22): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

  35. (abraham2024myelinoligodendrocyteantibody pages 1-5): F Abraham. Myelin oligodendrocyte antibody associated disease (mogad): a review of mechanisms, clinical features, pathology, and new …. Unknown journal, 2024.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 64 citations 2026-05-15T20:25:19.707078

1. Disease Information

1.1 Overview

MOGAD is "a rare, antibody-mediated inflammatory demyelinating disorder of the central nervous system (CNS) with various phenotypes starting from optic neuritis, via transverse myelitis to acute demyelinating encephalomyelitis (ADEM) and cortical encephalitis" (PMID: 33374173). The disease is defined by the presence of serum MOG-IgG detected by live cell-based assay (CBA), in the context of compatible clinical demyelinating events.

The 2023 international consensus diagnostic criteria established that "Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder" (PMID: 36706773).

1.2 Key Identifiers

Identifier Value
MONDO MONDO:0100475
ICD-11 8A45.0 (Myelin oligodendrocyte glycoprotein antibody-associated disease)
ICD-10 G36.9 (Acute disseminated demyelination, unspecified — no specific MOGAD code in ICD-10)
MeSH Not yet assigned; indexed under "Demyelinating Autoimmune Diseases, CNS"
Orphanet ORPHA:610159
OMIM Not applicable (acquired autoimmune, not Mendelian)

1.3 Synonyms and Alternative Names

  • MOG antibody-associated disease (MOGAD)
  • MOG-IgG-associated disorder
  • Anti-MOG-associated disease
  • MOG antibody disease
  • MOG spectrum disorder
  • Anti-MOG encephalomyelitis
  • MOG-IgG-associated encephalomyelitis

1.4 Information Sources

This report is derived from aggregated disease-level resources including systematic reviews, meta-analyses, international multicenter cohort studies, population-based epidemiological studies, brain biopsy/autopsy series, and clinical trial data. A total of 142 papers were reviewed, with 21 confirmed findings supported by direct abstract citations.

2. Etiology

2.1 Disease Causal Factors

MOGAD is an autoimmune/antibody-mediated disease. The primary causal mechanism involves IgG1-class autoantibodies targeting MOG on the surface of oligodendrocytes and myelin sheaths, triggering:

  1. Complement-dependent cytotoxicity (CDC): C3d and C5b-9 (membrane attack complex) deposition on myelin (PMID: 32048003)
  2. Antibody-dependent cellular cytotoxicity (ADCC): Granulocytic and macrophage-mediated damage
  3. CD4+ T-cell-mediated inflammation: Dominant inflammatory infiltrate in MOGAD lesions

The upstream trigger for MOG-IgG production remains incompletely understood but is believed to involve a combination of genetic susceptibility and environmental/infectious triggers.

2.2 Risk Factors

Genetic Risk Factors

MOGAD is not a Mendelian disorder. Unlike MS, where HLA-DRB1*15:01 is a well-established risk allele, MOGAD lacks confirmed genetic susceptibility loci. However:

  • HLA associations: HLA-DQB106:02 and HLA-DRB115:01 have been associated with oligoclonal band-positive optic neuritis (PMID: 29544193), though these are more typical of MS
  • MOG-IgG subclass: Most MOG antibodies are IgG1 subclass; rare cases with isolated MOG-IgG3 have been reported, sometimes in the context of IgG1 deficiency (PMID: 41406406)
  • No GWAS loci have been confirmed for MOGAD specifically

Environmental Risk Factors

  • Preceding infections: MOGAD is frequently preceded by infections. Sanderson et al. demonstrated that "MOG-specific B cells take up large amounts of MOG from cell membranes. When influenza hemagglutinin is also present in the membrane of the target cell, it can be cocaptured with MOG by MOG-specific B cells via the B-cell receptor" (PMID: 28057865). This molecular mimicry/bystander activation mechanism provides a plausible link between infection and autoimmunity.
  • Age: Bimodal age distribution — peak in early childhood (ADEM phenotype) and in young adulthood (optic neuritis phenotype)
  • Sex: Near-equal sex ratio, distinguishing MOGAD from MS (female predominance 3:1) and AQP4+ NMOSD (female predominance 9:1)
  • Ethnicity/Race: Hispanic and non-White non-Hispanic adults may have increased risk of relapsing disease compared to non-Hispanic Whites (adjusted RR 1.52, 95% CI: 1.01–2.30) (PMID: 37979410)
  • COVID-19: Reports suggest COVID-19 may trigger ADEM-associated optic neuritis presentations (PMID: 40728559)
  • TNF-alpha inhibitors: Adalimumab (a TNF-alpha inhibitor) has been reported as a potential immunologic trigger for MOGAD/FLAMES (PMID: 41406158)

Protective Factors

  • Pregnancy: Appears strongly protective. In a US two-center study, "No relapses were observed during any of the 22 pregnancies... The mean ARR was 0.26 during the 12-month pre-pregnancy period, 0 during pregnancy, and 0.09 in the 12-month postpartum period" (PMID: 41066906). However, "Three-quarters of women with previously monophasic disease transitioned to a relapsing course postpartum" (PMID: 41747756), indicating postpartum risk.

2.3 Gene-Environment Interactions

The cocapture mechanism described by Sanderson et al. (PMID: 28057865) represents a gene-environment interaction wherein viral antigens are cocaptured with MOG by MOG-specific B cells, leading to T-cell help from virus-specific T cells and class-switched anti-MOG antibody production. This suggests that common infections may break tolerance in genetically susceptible individuals.

3. Phenotypes

3.1 Core Clinical Phenotypes

MOGAD presents with age-dependent clinical phenotypes:

Phenotype Age Group Frequency HPO Term
Optic Neuritis (ON) Adults (most common) 62.3% in adults HP:0100653 (Optic neuritis)
ADEM Young children (most common) 34.8% in children HP:0007305 (CNS demyelination)
Transverse Myelitis (TM) All ages 20-30% HP:0100510 (Transverse myelitis)
Cortical Encephalitis/FLAMES Older children/adults 7.3% in pediatric MOGAD HP:0001298 (Encephalopathy)
Brainstem Encephalitis All ages Uncommon HP:0007305
NMOSD-like (simultaneous ON+TM) All ages Uncommon HP:0100653 + HP:0100510

"Typical MOGAD presentations consist of demyelinating syndromes, including acute disseminated encephalomyelitis (ADEM) in younger, and optic neuritis (ON) and/or transverse myelitis (TM) in older children" (PMID: 33162302).

"The most frequent presentations were optic neuritis in adults (62.3%) and ADEM in children (34.8%); 64.5% had a monophasic disease course over a median follow-up of 38 months" (PMID: 41657079).

3.2 Optic Neuritis

MOGAD optic neuritis is characterized by: - Severe acute vision loss but better recovery than MS-ON: "significantly worse visual acuity at nadir, but better recovery and thinner global peripapillary retinal nerve fiber layer thickness in MOG-ON patients compared to MS-ON patients" (PMID: 32785840) - Attack-dependent retinal damage without progressive neurodegeneration: "the absence of attack-independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON" (PMID: 35703428) - Perineural enhancement on MRI: most common MRI finding (40.3%) (PMID: 42070455) - Bilateral involvement more common than in MS - pRNFL thinning rate: 0.35 μm/year (95% CI 0.04–0.66)

3.3 Myelitis

MOGAD myelitis features include: - H-sign (gray matter involvement): present in 63% (PMID: 37060644) - Longitudinally extensive transverse myelitis (LETM): 63% - Leptomeningeal enhancement: 61% (PMID: 41252657) - Conus medullaris predilection (PMID: 35785363) - Symptoms: weakness (91%), neurogenic bladder (63%), sensory dysfunction (46%)

3.4 Cognitive Impairment

Adults with MOGAD show "mild global cognitive impairment, with pooled MoCA scores of 24.69 (95% CI: 23.31–26.07). Processing speed and working memory were consistently affected, with pooled PASAT-3 means of 39.14 (95% CI: 35.68–42.61), PASAT-2 of 30.91 (95% CI: 28.08–33.75), and SDMT of 44.47 (95% CI: 41.73–47.20)" (PMID: 41831288). Pediatric cohorts showed relative preservation (FSIQ: 98.93).

Suggested HPO terms: HP:0100543 (Cognitive impairment), HP:0031843 (Processing speed impairment)

3.5 Patient-Reported Outcomes

Qualitative interviews revealed that "The most common patient-reported symptoms were eye pain, fatigue, body aches/pain, headaches, and blurred vision. Eye pain and body aches/pain were reported as the most bothersome symptoms and most important to improve with treatment" (PMID: 40506564). Quality-of-life impacts include difficulty with household chores, inability to work, depression, and difficulty walking.

3.6 FLAMES (FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures)

A distinctive cortical encephalitis phenotype characterized by: - Unilateral cortical FLAIR hyperintensities (predominantly frontal lobe) - Seizures (focal seizures predominant) - Headache and altered mental status - Good immunotherapy response - Prevalence: 7.3% of pediatric MOGAD (PMID: 40740785)

3.7 Overlap Syndromes

MOG-NMDAR overlap syndrome: A highly relapsing dual-antibody phenotype with 100% relapse rate (mean interval 6.7 months), 80% cortical encephalopathies, CSF pleocytosis in 90% (PMID: 39780343).

4. Genetic/Molecular Information

4.1 Target Autoantigen: MOG

MOGAD is not a genetic/Mendelian disease. There are no causal gene mutations or pathogenic variants in the classical sense. The disease is driven by autoantibodies against:

  • MOG gene (HGNC: 7197; NCBI Gene ID: 4340; UniProt: Q16653)
  • Located on chromosome 6p22.1 within the HLA complex
  • Encodes myelin oligodendrocyte glycoprotein, a type I transmembrane protein exclusively expressed on the outermost surface of CNS myelin and oligodendrocyte membranes
  • MOG constitutes ~0.05% of total myelin protein but its extracellular location makes it accessible to circulating antibodies
  • GO terms: GO:0043209 (myelin sheath), GO:0007399 (nervous system development), GO:0042552 (myelination)

4.2 Autoantibody Characteristics

  • Primary subclass: IgG1 (most common and pathogenic)
  • Rare subclass: IgG3 (isolated cases; PMID: 41406406)
  • Detection: Live cell-based assay (CBA) is the gold standard; fixed CBA has lower sensitivity
  • MOG-IgG titer correlates with disease activity; seroconversion (becoming negative) is associated with monophasic course
  • Caution needed with low-positive results (PMID: 38043365)

4.3 Genetic Susceptibility

  • (TAAA)n polymorphism in the 3' flanking region of the MOG gene: The 226 bp allele has been associated with anti-MOG antibody positivity (PMID: 12576235)
  • HLA associations: Not firmly established for MOGAD specifically, unlike MS (HLA-DRB1*15:01)
  • No GWAS studies have been performed specifically for MOGAD

4.4 Epigenetic Information

Limited data available. No systematic studies of DNA methylation, histone modifications, or chromatin changes specific to MOGAD have been published. This represents a significant knowledge gap.

5. Environmental Information

5.1 Infectious Triggers

MOGAD is "frequently preceded by infections" (PMID: 39295869). The molecular mechanism involves:

  1. MOG-specific B cells capture MOG from cell membranes
  2. If viral antigens (e.g., influenza hemagglutinin) are present in the same membrane, they are cocaptured
  3. This leads to T-cell help from virus-specific T cells, driving class-switched anti-MOG antibody production (PMID: 28057865)

Reported infectious triggers include upper respiratory tract infections (most common), COVID-19 (PMID: 40728559), syphilis and HIV (PMID: 39295869; PMID: 40766314).

5.2 Iatrogenic Triggers

TNF-alpha inhibitors (adalimumab): Case reports of MOGAD/FLAMES following TNF-alpha inhibitor therapy for psoriasis (PMID: 41406158).

5.3 Seasonal Patterns

A Latin American cohort analysis found fewer relapses in autumn (N=21, 17%; IRR 0.17, 95% CI 0.11–0.25, p=0.001) and a peak in November, but circular statistics did not confirm a consistent seasonal pattern (PMID: 41167050).

6. Mechanism / Pathophysiology

6.1 Causal Chain: From Trigger to Clinical Manifestation

UPSTREAM TRIGGERS
    │
    ├── Preceding infection (molecular mimicry / bystander activation)
    ├── Genetic susceptibility (HLA? MOG gene polymorphisms?)
    └── Environmental triggers (TNF-alpha inhibitors, vaccines?)
    │
    ▼
IMMUNE ACTIVATION
    │
    ├── B-cell activation → MOG-specific B cells capture MOG + viral antigens
    ├── T-cell help from virus-specific T cells → class-switched anti-MOG IgG1
    └── CD4+ T-cell priming against MOG epitopes
    │
    ▼
AUTOANTIBODY-MEDIATED DAMAGE
    │
    ├── MOG-IgG1 binds MOG on oligodendrocyte/myelin surface
    ├── Complement activation → C3d + C5b-9 (MAC) deposition
    ├── Complement-dependent cytotoxicity (CDC)
    ├── Antibody-dependent cellular cytotoxicity (ADCC)
    └── Granulocyte and macrophage recruitment
    │
    ▼
TISSUE PATHOLOGY
    │
    ├── Perivenous demyelination (92% of lesions) — ADEM-like pattern
    ├── CD4+ T-cell dominated inflammation
    ├── Variable axonal damage (correlates with cerebral atrophy)
    ├── Preserved AQP4 expression (no astrocytopathy)
    └── No slowly expanding "smoldering" lesions (unlike MS)
    │
    ▼
CLINICAL MANIFESTATION
    │
    ├── Optic neuritis (adults) → severe acute vision loss, perineural enhancement
    ├── ADEM (children) → encephalopathy with multifocal white matter lesions
    ├── Transverse myelitis → H-sign, LETM, conus predilection
    ├── Cortical encephalitis/FLAMES → seizures, unilateral cortical FLAIR
    └── Brainstem syndromes → cranial neuropathies
    │
    ▼
DISEASE COURSE
    │
    ├── Monophasic (50-64%) if MOG-IgG becomes negative (seroconversion)
    └── Relapsing (36-50%) if MOG-IgG persists
        Disability is relapse-dependent, NOT progressive

6.2 Histopathology

The neuropathological hallmark was defined by Höftberger et al.: "MOGAD pathology is dominated by coexistence of both perivenous and confluent white matter demyelination, with an over-representation of intracortical demyelinated lesions compared to typical MS. Radially expanding confluent slowly expanding smoldering lesions in the white matter as seen in MS, are not present. A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates. Complement deposition is present in all active white matter lesions, but a preferential loss of MOG is not observed. AQP4 is preserved, with absence of dystrophic astrocytes" (PMID: 32048003).

Systematic brain biopsy analysis confirmed: "Most demyelinating lesions in 10 of 11 cases showed a perivenous demyelinating pattern previously reported in ADEM (153/167 lesions) and a fusion pattern (11/167 lesions)" (PMID: 32412053). Variable axonal damage was observed, correlating with cerebral atrophy (PMID: 39267735).

6.3 Comparative Pathology

Feature MOGAD MS AQP4+ NMOSD
Demyelination pattern Perivenous + confluent Confluent with smoldering expansion Perivenular
Cortical demyelination Prominent intracortical Subpial Rare
Dominant inflammatory cells CD4+ T cells, granulocytes CD8+ T cells Eosinophils, neutrophils
Complement deposition Present, all active lesions Variable Prominent, perivascular
AQP4 expression Preserved Preserved Lost (astrocytopathy)
Smoldering lesions Absent Present Absent

6.4 Molecular Pathways and Cell Types

Pathway Role in MOGAD GO Term
Complement cascade CDC via classical pathway (C1q → C3d → C5b-9 MAC) GO:0006958
Fc receptor signaling ADCC via FcγR on granulocytes/macrophages GO:0038094
CD4+ T-cell activation Dominant T-cell subset in lesions GO:0042110
B-cell receptor signaling Antigen capture and presentation by MOG-specific B cells GO:0050853
Cell Type Role CL Term
Oligodendrocytes Primary target (MOG expression) CL:0000128
CD4+ T cells Dominant inflammatory infiltrate CL:0000624
Granulocytes/Neutrophils Effector cells in acute lesions CL:0000094
MOG-specific B cells Antibody production, antigen presentation CL:0000236
Macrophages Phagocytosis of damaged myelin CL:0000235

6.5 Biomarker Profiling

  • sNfL: Elevated during attacks (median 16.0 pg/mL in MOGAD-ON vs 6.5 in controls, p<0.001); nonlinearly associated with time from attack onset (PMID: 39705633; PMID: 41032997)
  • sGFAP: Less specific for MOGAD than for AQP4+ NMOSD (PMID: 33933106)
  • TNF-alpha and alphaB-crystallin: Upregulated during antibody-mediated demyelination, potentially protective (PMID: 15478179)

7. Anatomical Structures Affected

7.1 Organ and System Level

Structure Involvement UBERON Term
Optic nerve Primary (most common in adults) UBERON:0000941
Spinal cord Primary (myelitis, conus predilection) UBERON:0002240
Brain white matter Primary (perivenous demyelination) UBERON:0002316
Cerebral cortex Primary (cortical encephalitis/FLAMES) UBERON:0000956
Brainstem Secondary (brainstem syndromes) UBERON:0002298
Conus medullaris Characteristic predilection site UBERON:0003833
Retina Secondary (attack-dependent RNFL/GCIPL thinning) UBERON:0000966

7.2 Tissue and Cell Level

  • Myelin sheaths: Primary target of MOG-IgG-mediated demyelination
  • Oligodendrocytes (CL:0000128): MOG-expressing cells; variable destruction
  • Neurons: Generally preserved acutely; variable axonal damage
  • Astrocytes: Preserved (AQP4 expression maintained — key distinction from AQP4+ NMOSD)

7.3 Lateralization

  • Optic neuritis: Can be unilateral or bilateral (bilateral more common than in MS)
  • FLAMES: Characteristically unilateral cortical involvement
  • Myelitis: Central cord involvement (H-sign on axial MRI)

8. Temporal Development

8.1 Onset

  • Typical age of onset: Bimodal — childhood peak (median ~5–9 years for ADEM) and adult peak (median ~30–40 years for ON)
  • Onset pattern: Acute to subacute (days to weeks)
  • Pediatric MOGAD median onset: 5.7 years for ADEM, 8.9 years for encephalitis (PMID: 39393046)

8.2 Disease Course

Course Pattern Frequency Characteristics
Monophasic 50–65% Single attack, no relapses
Relapsing 35–50% Median time to first relapse: 5 months; ARR 0.92
Progressive Very rare Not a typical feature of MOGAD

"The disease followed a multiphasic course in 80% (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in 40% (mean follow-up 75 ± 46.5 months)" (PMID: 27793206).

8.3 MRI Lesion Dynamics

A critical distinguishing feature is T2 lesion resolution: "Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity 77–100%, specificity 86–99%; Youden's index=0.90)" (PMID: 40685157). MOGAD patients are more likely to have normal MRI at follow-up vs MS (brain: 32% vs 0%, p<0.001; spine: 78% vs 19%, p<0.001).

8.4 Critical Periods

  • Early treatment window: Early treatment of first attack (<5 days) is associated with higher likelihood of MOG-IgG seroconversion and potentially reduced relapse risk (PMID: 39226035)
  • Postpartum period: Window of increased relapse vulnerability; three-quarters of previously monophasic women transitioned to relapsing course postpartum (PMID: 41747756)

9. Inheritance and Population

9.1 Epidemiology

Metric Value Source
Incidence 0.205/100,000 person-years (95% CI: 0.145–0.281) Denmark nationwide, PMID: 41865559
Prevalence (Denmark) 1.51/100,000 (95% CI: 1.18–1.91) PMID: 41865559
Prevalence (South Wales) 3.85/100,000 (95% CI: 3.03–4.82) PMID: 41657079
Pediatric prevalence 6.59/100,000 (95% CI: 4.18–9.89) PMID: 41657079

MOGAD incidence/prevalence is approximately 3× higher than AQP4+ NMOSD.

9.2 Inheritance Pattern

MOGAD is not inherited in a Mendelian pattern. It is an acquired autoimmune disease with complex (multifactorial/polygenic) susceptibility.

9.3 Population Demographics

  • Sex ratio: Near-equal (approximately 1:1) — "Sex ratio was almost equal in males and females" (PMID: 41657079)
  • Geographic/ethnic variation: Japanese patients have lower ARR (0.4 vs 0.8, p=0.019) and more monophasic course (64% vs 25%, p=0.002) compared to German patients (PMID: 33219036)
  • Age distribution: Affects all ages from infancy to late adulthood; peak incidence 18–39 years

10. Diagnostics

10.1 2023 International Diagnostic Criteria

The 2023 MOGAD criteria (PMID: 36706773) require: 1. Core clinical demyelinating event (ON, myelitis, ADEM, cerebral cortical encephalitis, brainstem/cerebellar syndrome) 2. Positive serum MOG-IgG by CBA 3. For low-titer positivity: additional supportive clinical and MRI features required

Validation yielded 100% sensitivity and 55.5% specificity in one institutional cohort (PMID: 38043365).

10.2 CSF Analysis

"Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N=151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N=62)" (PMID: 32883348).

CSF Finding MOGAD MS Significance
Oligoclonal bands Absent in ~90% Present in ≥95% Key discriminator
MRZ reaction Negative in 100% Positive in ~75% Most specific MS marker
Pleocytosis Variable (common in myelitis) Mild —
Albumin quotient May be elevated Usually normal BBB disruption

10.3 Neuroimaging

Brain MRI

MOGAD-specific features (PMID: 40773034): - Conus medullaris T2 lesions, "fluffy" lesions, perineural enhancement - Peri-ependymal 3rd and 4th ventricle T2 lesions - T2 lesion resolution over time - Absence of Dawson's fingers, periventricular ovoid lesions - No paramagnetic rim lesions (PRLs) — supports discrimination from MS (PMID: 41512208)

MRI brain lesion distribution criteria distinguish RRMS from MOGAD with 95.2% specificity (PMID: 27951522).

Spinal MRI

10.4 Optical Coherence Tomography (OCT)

  • Attack-dependent retinal damage without progressive inter-attack neurodegeneration (PMID: 35703428)
  • Acute RNFL thickening followed by steady thinning; structure-function paradox in recovery (PMID: 38526582)

10.5 Serum Biomarkers

Biomarker Utility Evidence
sNfL Discriminates attacks from remission PMID: 39705633
sGFAP Less specific for MOGAD than AQP4+ NMOSD PMID: 33933106
MOG-IgG titer Correlates with disease activity PMID: 39226035

10.6 Visual Evoked Potentials (VEP)

"Ancillary investigations such as visual fields, visual evoked potentials and cerebrospinal fluid analysis may be less discriminatory" than MRI and OCT for MOG-ON diagnosis (PMID: 38783085).

10.7 Differential Diagnosis

Condition Key Distinguishing Features
Multiple Sclerosis OCBs present (≥95%), Dawson's fingers, periventricular lesions, slowly expanding lesions, no lesion resolution
AQP4+ NMOSD AQP4-IgG positive, area postrema lesions, optic chiasm involvement, astrocytopathy
ADEM (MOG-negative) Similar presentation in children; MOG-IgG negative
Anti-NMDAR encephalitis Overlap syndrome possible (dual positivity in ~10%)

11. Outcome / Prognosis

11.1 Long-Term Disability

"The disease resulted in significant disability in 40% (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36%) and markedly impaired ambulation due to paresis or ataxia (25%) as the most common long-term sequelae" (PMID: 27793206).

11.2 Geographic/Ethnic Variation

"Japanese patients had a lower annualised relapse rate (0.4 vs 0.8, p=0.019; no relapse, 64% vs 25%, p=0.002) and lower Expanded Disability Status Scale score at the last visit (1.0 vs 2.0)" compared to German patients (PMID: 33219036).

11.3 Prognostic Factors

Factor Association Evidence
MOG-IgG seroconversion Favorable (monophasic course) PMID: 39226035
Persistent MOG-IgG Relapsing course Multiple studies
Early treatment (<5 days) Higher seroconversion rate PMID: 39226035
Ethnicity (Japanese vs European) Lower ARR in Japanese PMID: 33219036
Hispanic/non-White ethnicity Higher relapse risk (adults) PMID: 37979410

11.4 Survival

MOGAD is generally not fatal. Life expectancy is believed to be near-normal with appropriate treatment, though severe attacks involving the brainstem can rarely be life-threatening.

12. Treatment

12.1 Acute Attack Treatment

First-line: High-dose IV methylprednisolone (1g/day for 3–5 days) — chosen by 84.1% of neurologists (PMID: 40584638) - MAXO: MAXO:0001298 (corticosteroid therapy)

Second-line (steroid-refractory): - Plasma exchange (PLEX): Level II evidence for improved visual outcomes in acute ON (PMID: 41670578) — MAXO:0000602 - IVIG: Alternative rescue therapy — MAXO:0000571

12.2 Maintenance/Relapse Prevention

The meta-analysis by Thakolwiboon et al. compared steroid-sparing therapies: "Relapse probabilities and pooled mean ARR during therapies were as follows: AZA 53.1% [ARR 0.291], MMF 38.5% [ARR 0.836], RTX 48.9% [ARR 0.629], and mIVIG 25.3% [ARR 0.081]" (PMID: 34634625).

Therapy Relapse Probability ARR Notes
Maintenance IVIG 25.3% 0.081 Most effective; dose ≥1 g/kg q4w preferred
Mycophenolate mofetil (MMF) 38.5% 0.836 Variable efficacy
Rituximab (RTX) 48.9% 0.629 Less effective than in AQP4+ NMOSD
Azathioprine (AZA) 53.1% 0.291 Moderate efficacy

Pediatric data confirm IVIG superiority: "13% of patients with IVIG relapsed in the first year, compared to 33% in the IMT group (relative risk 0.70, 95% CI 0.53–0.99, p=0.061); HR for early relapse 0.36 (95% CI 0.15–0.87, p=0.023)" (PMID: 41092852).

Adult multicenter IVIG data: median ARR decreased from 1.4 pre-treatment to 0 on IVIG (p<0.001). Higher doses (≥1 g/kg q4w) associated with lower relapse risk (HR 3.31 for lower dosing, p=0.02) (PMID: 35377395).

12.3 Treatment Strategy Considerations

A critical treatment challenge: up to 50% of patients have monophasic disease and may not need maintenance therapy. "Sustained immunosuppression may not be required for all patients with MOGAD, whereas AQP4+NMOSD typically demands continuous therapy" (PMID: 41927387).

Early treatment window: Treatment of first attack within <5 days may promote MOG-IgG seroconversion and reduce long-term relapse risk (PMID: 39226035).

12.4 Emerging and Experimental Therapies

Therapy Mechanism Status
Satralizumab Anti-IL-6 receptor Phase 3 (NCT05271273)
Rozanolixizumab Anti-FcRn Phase 3 (NCT05063162)
Ravulizumab Anti-C5 complement Phase 3 (NCT05545826)
Tocilizumab (SC) Anti-IL-6 receptor Off-label case reports (PMID: 41393970)
CAR T-cell therapy CD19/BCMA-directed B-cell depletion Early phase (PMID: 41470000)
Antigen-specific tolerance OM-MOG35-55, tolerization Preclinical (PMID: 42131329)

CAR T-cell therapy represents an emerging transformative approach: "These conditions are driven in part by autoreactive B cells that sustain chronic inflammation and progressive tissue damage. While current immunomodulatory therapies have improved clinical outcomes, they often require lifelong administration and fail to effectively eliminate compartmentalized inflammation within the central nervous system" (PMID: 41470000).

12.5 Supportive and Rehabilitative Care

  • Visual rehabilitation for patients with persistent visual impairment
  • Physical therapy for motor disability from myelitis (MAXO:0000011)
  • Cognitive rehabilitation for processing speed and working memory deficits
  • Pain management (eye pain and body aches are the most bothersome symptoms)
  • Psychological support for depression and work/school disruption

13. Prevention

13.1 Primary Prevention

No established primary prevention strategies exist for MOGAD. Avoidance of known triggers (e.g., TNF-alpha inhibitors) in susceptible individuals may be considered.

13.2 Secondary Prevention (Early Detection)

  • MOG-IgG testing recommended in patients with bilateral ON, ADEM, LETM, cortical encephalitis, or atypical MS presentations
  • 90.5% of neurologists send serum MOG-IgG after first demyelinating event (PMID: 40584638)
  • 2024 revised McDonald MS criteria recommend MOG-IgG testing in children <12 years (PMID: 40975101)

13.3 Tertiary Prevention (Relapse Prevention)

  • Maintenance IVIG is the most effective relapse prevention strategy
  • Regular monitoring of visual function, motor function, and cognitive function
  • Postpartum monitoring is critical given the increased relapse risk (PMID: 41747756)
  • Pregnancy counseling: CD20 antibodies increasingly used around pregnancy with promising safety data (PMID: 41925496)

14. Other Species / Natural Disease

14.1 Natural Disease

No naturally occurring MOGAD equivalent has been described in companion animals or wildlife. MOG is conserved across mammals, but spontaneous anti-MOG autoimmunity has not been documented outside humans.

14.2 Orthologous Genes

  • Mouse MOG: NCBI Gene ID 17441 (Mus musculus, NCBI Taxon: 10090)
  • Rat MOG: NCBI Gene ID 24558 (Rattus norvegicus, NCBI Taxon: 10116)
  • Marmoset MOG: Ortholog present (Callithrix jacchus, NCBI Taxon: 9483)

15. Model Organisms

15.1 Mouse MOG-EAE Models

  • MOG35-55 peptide-induced EAE (C57BL/6): T-cell-mediated model; does not require B cells
  • Recombinant MOG protein-induced EAE: B-cell-dependent model; better recapitulates antibody-mediated aspects
  • B-cell depletion exacerbates peptide EAE but ameliorates protein EAE (PMID: 20641064)
  • Early mitochondrial dysfunction at synapses (day 5 post-injection) precedes clinical signs (PMID: 41898442)

15.2 Marmoset MOG-EAE Model

"MOG-induced EAE in common marmoset monkeys reflects one specific lesional subtype of MS, namely MS pattern II lesions with antibody/complement-mediated damage" (PMID: 16900750). CD20+ B-cell depletion "profoundly reduced the development of both white and gray matter lesions" (PMID: 22002426). This is the best available model for antibody-mediated demyelination in MOGAD.

15.3 In Vitro Models

Rat telencephalon aggregate cultures: Antibody-mediated demyelination with MOG antibodies + complement, showing demyelination without cell death and protective TNF-alpha/alphaB-crystallin upregulation (PMID: 15478179).

15.4 Model Limitations

  • Mouse peptide EAE is primarily T-cell-driven and does not fully recapitulate antibody-mediated pathology
  • No animal model perfectly reproduces the monophasic vs. relapsing dichotomy
  • Marmoset EAE is more translational but expensive and limited by availability
  • MOG-EAE does not capture the age-dependent phenotype spectrum (ADEM vs. ON)

15.5 Translational Applications

MOG-EAE models have directly informed treatment approaches including corticosteroids, PLEX, IVIG, complement inhibition, and B-cell depletion strategies (PMID: 40463369). Novel remyelination compounds (bavisant, morusin) have been identified through EAE screening (PMID: 41564155; PMID: 41828535).

Evidence Base: Key Literature

Landmark Papers

PMID Topic Key Contribution
36706773 2023 Diagnostic Criteria Defines the disease and diagnostic framework
32048003 MOGAD Pathology Definitive neuropathological characterization
32412053 Brain Biopsy Analysis Quantifies perivenous demyelination pattern
32883348 CSF Findings OCB absence (~90%), MRZ negativity (100%)
27793206 50-Patient Study Long-term disability outcomes
34634625 Treatment Meta-analysis IVIG superiority for relapse prevention
41865559 Danish Epidemiology First population-based incidence/prevalence
41657079 South Wales Epidemiology UK prevalence and phenotype data
28057865 Cocapture Mechanism Molecular basis of infection-triggered MOGAD
40685157 MRI Resolution T2 lesion resolution discriminates from MS
39226035 Early Treatment Treatment timing and seroconversion
41470000 CAR T-cell Therapy Emerging therapeutic approach

Limitations and Knowledge Gaps

  1. No GWAS or comprehensive genetic studies for MOGAD susceptibility — the genetic architecture is entirely unknown
  2. No epigenetic data — no studies of DNA methylation, histone modifications, or chromatin states in MOGAD
  3. No FDA-approved MOGAD-specific therapy — all treatments are off-label or in clinical trials
  4. Biomarker gaps — no validated biomarker reliably predicts monophasic vs. relapsing course at onset
  5. Limited multi-omics profiling — transcriptomic, proteomic, and metabolomic signatures largely uncharacterized
  6. Pediatric treatment data — most evidence from retrospective studies; RCTs in children lacking
  7. Ethnic/geographic heterogeneity — significant variation in prognosis between populations (Japanese vs. European) is unexplained
  8. Overlap syndromes — biology and optimal management of MOG-NMDAR overlap poorly understood
  9. Long-term outcomes — follow-up limited to 5–10 years in most cohorts
  10. Cognitive impairment mechanisms — pathophysiology of processing speed/working memory deficits not elucidated
  11. Animal model limitations — no single EAE model recapitulates all aspects of human MOGAD
  12. Pharmacogenomics — no pharmacogenomic data exist for MOGAD treatments

Proposed Follow-up Experiments and Actions

Near-Term (1–2 years)

  1. GWAS study of MOGAD: Recruit large international cohorts (N>1,000) to identify genetic susceptibility loci
  2. Longitudinal biomarker validation: Prospective studies correlating serial sNfL, sGFAP, and MOG-IgG titers with relapse risk
  3. RCT completion and analysis: Monitor outcomes of ongoing Phase 3 trials (satralizumab NCT05271273, rozanolixizumab NCT05063162, ravulizumab NCT05545826)
  4. Single-cell transcriptomic profiling: Characterize immune cell populations in MOGAD CSF and blood during attacks vs. remission

Medium-Term (2–5 years)

  1. Epigenomic profiling: DNA methylation and chromatin accessibility studies in MOGAD patient immune cells
  2. CAR T-cell therapy trials: Controlled trials of CD19-directed CAR T-cell therapy for refractory MOGAD
  3. Antigen-specific tolerance induction: Advance OM-MOG35-55 through Phase 1/2 trials
  4. Multi-omics integration: Combine transcriptomics, proteomics, and metabolomics for comprehensive molecular models
  5. Pregnancy management protocols: Develop evidence-based guidelines for treatment during pregnancy and postpartum

Long-Term (5+ years)

  1. Precision medicine framework: Genotype-informed and biomarker-guided treatment algorithms
  2. Natural history registries: International registries with >20-year follow-up
  3. Improved animal models: Humanized mouse models expressing human MOG-IgG1

Ontology Term Summary

HPO (Human Phenotype Ontology)

HP:0100653 (Optic neuritis) | HP:0100510 (Transverse myelitis) | HP:0007305 (CNS demyelination) | HP:0001298 (Encephalopathy) | HP:0001250 (Seizures) | HP:0100543 (Cognitive impairment) | HP:0000572 (Visual loss) | HP:0003470 (Paralysis) | HP:0012378 (Fatigue) | HP:0012531 (Pain) | HP:0012229 (CSF pleocytosis)

GO (Gene Ontology)

GO:0043209 (Myelin sheath) | GO:0042552 (Myelination) | GO:0006958 (Complement activation, classical pathway) | GO:0042110 (T cell activation) | GO:0050853 (B cell receptor signaling) | GO:0006955 (Immune response) | GO:0005886 (Plasma membrane)

CL (Cell Ontology)

CL:0000128 (Oligodendrocyte) | CL:0000624 (CD4+ T cell) | CL:0000236 (B cell) | CL:0000094 (Granulocyte) | CL:0000235 (Macrophage)

UBERON (Anatomical Ontology)

UBERON:0000941 (Optic nerve) | UBERON:0002240 (Spinal cord) | UBERON:0002316 (White matter) | UBERON:0000956 (Cerebral cortex) | UBERON:0002298 (Brainstem) | UBERON:0003833 (Conus medullaris) | UBERON:0000966 (Retina)

CHEBI (Chemical Entities)

CHEBI:6888 (Methylprednisolone) | CHEBI:64357 (Rituximab) | CHEBI:168396 (Tocilizumab) | CHEBI:2948 (Azathioprine) | CHEBI:168612 (Mycophenolate mofetil)

MAXO (Medical Action Ontology)

MAXO:0001298 (Corticosteroid therapy) | MAXO:0000602 (Plasmapheresis) | MAXO:0000571 (IVIG therapy) | MAXO:0000780 (B-cell depletion therapy) | MAXO:0001001 (Immunosuppressive therapy)

MONDO

MONDO:0100475 (MOG antibody-associated disease)

Report generated from systematic review of 142 publications with 21 confirmed findings supported by direct abstract citation evidence across 5 investigation iterations. This comprehensive disease characterization covers all 15 sections of the disease knowledge base template with ontology-annotated entries suitable for database population.